{"protocolSection":{"identificationModule":{"nctId":"NCT04917861","orgStudyIdInfo":{"id":"mRNA-1893-P201"},"secondaryIdInfos":[{"id":"HHSO100201600029C","type":"OTHER_GRANT","domain":"BARDA"}],"organization":{"fullName":"ModernaTX, Inc.","class":"INDUSTRY"},"briefTitle":"A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas","officialTitle":"A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose Confirmation Study to Evaluate the Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Adults Aged 18 Through 65 Years and Living in Endemic and Non-Endemic Flavivirus Areas"},"statusModule":{"statusVerifiedDate":"2025-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-06-07","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-07-26","type":"ACTUAL"},"completionDateStruct":{"date":"2024-07-26","type":"ACTUAL"},"studyFirstSubmitDate":"2021-06-02","studyFirstSubmitQcDate":"2021-06-02","studyFirstPostDateStruct":{"date":"2021-06-08","type":"ACTUAL"},"resultsFirstSubmitDate":"2025-07-25","resultsFirstSubmitQcDate":"2025-09-05","resultsFirstPostDateStruct":{"date":"2025-09-25","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-09-05","lastUpdatePostDateStruct":{"date":"2025-09-25","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"ModernaTX, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This clinical study will evaluate the safety, tolerability, and reactogenicity of 2 dose levels of messenger RNA (mRNA)-1893 Zika vaccine in comparison to a placebo control in healthy participants who are flavivirus-seronegative and in participants who are flavivirus-seropositive."},"conditionsModule":{"conditions":["Zika Virus"],"keywords":["Flavivirus","mRNA-1893","Zika vaccine","Moderna"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":808,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"mRNA-1893 Low Dose (2-Dose Regimen)","type":"EXPERIMENTAL","description":"Participants will receive mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day (-3/+7 days) interval between vaccinations (administered on Day 1 and Day 29).","interventionNames":["Biological: mRNA-1893"]},{"label":"mRNA-1893 High Dose (2-Dose Regimen)","type":"EXPERIMENTAL","description":"Participants will receive mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day (-3/+7 days) interval between vaccinations (administered on Day 1 and Day 29).","interventionNames":["Biological: mRNA-1893"]},{"label":"mRNA-1893 High Dose (1-Dose Regimen)","type":"EXPERIMENTAL","description":"Participants will receive placebo matching to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There will be 28-day (-3/+7 days) interval between vaccinations.","interventionNames":["Biological: mRNA-1893","Biological: Placebo"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive placebo matching to mRNA-1893 administered as a 2-dose regimen with 28-day (-3/+7 days) interval between vaccinations (administered on Day 1 and Day 29).","interventionNames":["Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"mRNA-1893","description":"Solution for injection","armGroupLabels":["mRNA-1893 High Dose (1-Dose Regimen)","mRNA-1893 High Dose (2-Dose Regimen)","mRNA-1893 Low Dose (2-Dose Regimen)"],"otherNames":["Zika vaccine"]},{"type":"BIOLOGICAL","name":"Placebo","description":"0.9% sodium chloride solution for injection","armGroupLabels":["Placebo","mRNA-1893 High Dose (1-Dose Regimen)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)","description":"Solicited ARs (local and systemic) were collected in the electronic diary. Local ARs included: pain, erythema (redness), swelling/induration (hardness). Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, body temperature (potentially fever), and chills. A summary of all serious adverse events (SAEs) and all nonserious adverse events (AEs) (\"Other\"), regardless of causality, is in Reported \"Adverse Events\" section.","timeFrame":"Up to 7 days post-vaccination"},{"measure":"Number of Participants With Unsolicited Adverse Events (AEs)","description":"An unsolicited AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Unsolicited AEs were AEs that were not included in the protocol-defined solicited ARs. A treatment-emergent adverse event (TEAE) was defined as any AE not present before exposure to vaccine or any AE already present that worsened in intensity or frequency after exposure. A summary of all SAEs and all nonserious AEs (\"Other\"), regardless of causality, is located in the Reported \"Adverse Events\" section.","timeFrame":"Up to 28 days post-vaccination"},{"measure":"Number of Participants With Serious Adverse Events (SAEs), AEs of Special Interest (AESIs)","description":"An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, was a congenital anomaly/birth defect, or was an important medical event. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor were required. A summary of all SAEs and all nonserious AEs (\"Other\"), regardless of causality, is located in the Reported \"Adverse Events\" section.","timeFrame":"Day 1 through Day 196 for Main Study and Day 197 through Day 700 for Extension Period"},{"measure":"Number of Participants With Medically Attended AEs (MAAEs)","description":"An MAAE was an AE that led to an unscheduled visit to a healthcare practitioner. Note that the generation of the tables for the MAAE data for the Main Study occurred after the start of the Extension Period. Therefore, some of the MAAE data for this outcome measure may appear both in the Main Study and the Extension Period. A summary of all SAEs and all nonserious AEs (\"Other\"), regardless of causality, is located in the Reported \"Adverse Events\" section.","timeFrame":"Day 1 through Day 196 for Main Study and Day 197 through Day 700 for Extension Period"},{"measure":"Geometric Mean Titer (GMT) of Zika Virus (ZIKV)-Specific Neutralizing Antibodies (nAbs) at Day 57, as Measured by 50% Plaque Reduction Neutralization Test (PRNT50)","description":"Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5 \\* LLOQ. Values that were greater than the upper limit of quantification (ULOQ) were converted to the ULOQ. LLOQ=91; ULOQ=24814. 95% confidence interval (CI) was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation.","timeFrame":"Day 57"},{"measure":"GMT of ZIKV-specific nAbs at Day 57, as Measured by 80% Plaque Reduction Neutralization Test (PRNT80)","description":"Antibody values reported as below the LLOQ were replaced by 0.5 \\* LLOQ. Values that were greater than the ULOQ were converted to the ULOQ. LLOQ=91; ULOQ=24814. 95% CI was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation.","timeFrame":"Day 57"},{"measure":"Percentage of Participants With Seroconversion at Day 57, as Measured by PRNT50","description":"Seroconversion was defined as an increase in ZIKV-specific nAb titer from below the LLOQ to a titer equal to or above LLOQ, or an increase of at least 4-fold in ZIKV-specific nAb titer in participants with pre-existing nAb titers. LLOQ=91; ULOQ=24814.","timeFrame":"Day 57"},{"measure":"Percentage of Participants With Seroconversion at Day 57, as Measured by PRNT80","description":"Seroconversion was defined as an increase in ZIKV-specific nAb titer from below the LLOQ to a titer equal to or above LLOQ, or an increase of at least 4-fold in ZIKV-specific nAb titer in participants with pre-existing nAb titers. LLOQ=91; ULOQ=24814.","timeFrame":"Day 57"}],"secondaryOutcomes":[{"measure":"GMT of ZIKV-Specific nAbs at Days 1, 8, 29, and 36, as Measured by PRNT50 and PRNT80","description":"Antibody values reported as below the LLOQ were replaced by 0.5 \\* LLOQ. Values that were greater than the ULOQ were converted to the ULOQ. LLOQ=91; ULOQ=24814. 95% CI was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation.","timeFrame":"Days 1, 8, 29, and 36"},{"measure":"GMT of ZIKV-Specific nAbs at Days 1, 8, 29, 36, and 57, as Measured by Microneutralization (MN)","description":"Antibody values reported as below the LLOQ were replaced by 0.5 \\* LLOQ. Values that were greater than the ULOQ were converted to the ULOQ. LLOQ=28; ULOQ=11589. 95% CI was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation.","timeFrame":"Days 1, 8, 29, 36, and 57"},{"measure":"Geometric Mean Fold Rise (GMFR) of ZIKV-Specific nAbs at Days 8, 29, 36, and 57, as Measured by PRNT50 and PRNT80","description":"Antibody values reported as below the LLOQ were replaced by 0.5 \\* LLOQ. Values that were greater than the ULOQ were converted to the ULOQ. LLOQ=91; ULOQ=248. 95% CI was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation.","timeFrame":"Days 8, 29, 36, and 57"},{"measure":"GMFR of ZIKV-Specific nAbs at Days 8, 29, 36, and 57, as Measured by MN","description":"Antibody values reported as below the LLOQ were replaced by 0.5 \\* LLOQ. Values that were greater than the ULOQ were converted to the ULOQ. LLOQ=28; ULOQ=11589. 95% CI was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation.","timeFrame":"Days 8, 29, 36, and 57"},{"measure":"Percentage of Participants With Seroconversion at Days 8, 29, and 36, as Measured by PRNT50 and PRNT80","description":"Seroconversion was defined as an increase in ZIKV-specific nAb titer from below the LLOQ to a titer equal to or above LLOQ, or an increase of at least 4-fold in ZIKV-specific nAb titer in participants with pre-existing nAb titers. LLOQ=91; ULOQ=24814.","timeFrame":"Days 8, 29, and 36"},{"measure":"Percentage of Participants With Seroconversion at Days 8, 29, 36, and 57, as Measured by MN","description":"Seroconversion was defined as an increase in ZIKV-specific nAb titer from below the LLOQ to a titer equal to or above LLOQ, or an increase of at least 4-fold in ZIKV-specific nAb titer in participants with pre-existing nAb titers. LLOQ=28; ULOQ=11589.","timeFrame":"Days 8, 29, 36, and 57"},{"measure":"Percentage of Initially Seronegative Participants With a Seroresponse at Days 8, 29, and 36, as Measured by PRNT50 and PRNT80","description":"Seroresponse was defined as an increase in ZIKV-specific nAb titer from below the LLOQ to greater than or equal to the LLOQ. LLOQ=91; ULOQ=24814.","timeFrame":"Days 8, 29, and 36"},{"measure":"Percentage of Initially Seronegative Participants With a Seroresponse at Days 8, 29, 36, and 57, as Measured by MN","description":"Seroresponse was defined as an increase in ZIKV-specific nAb titer from below the LLOQ to greater than or equal to the LLOQ. LLOQ=28; ULOQ=11589.","timeFrame":"Days 8, 29, 36, and 57"},{"measure":"Percentage of Initially Seropositive Participants With a 2-Fold Increase in ZIKV-Specific nAb Titers as Compared With Baseline, as Measured by PRNT50 and PRNT80","description":"≥2-fold increase from baseline was defined as a ≥2 \\* LLOQ for participants with baseline undetectable antibody titer, or a 2-times or higher ratio in participants with pre-existing nAb titers. LLOQ=91","timeFrame":"Days 8, 29, 36, and 57"},{"measure":"Percentage of Initially Seropositive Participants With a 4-Fold Increase in ZIKV-Specific nAb Titers as Compared With Baseline, as Measured by PRNT50 and PRNT80","description":"≥4-fold increase from baseline was defined as a ≥4 \\* LLOQ for participants with baseline undetectable antibody titer, or a 4-times or higher ratio in participants with pre-existing nAb titers. LLOQ=91","timeFrame":"Days 8, 29, 36, and 57"},{"measure":"Percentage of Initially Seropositive Participants With a 2-Fold Increase in ZIKV-Specific nAb Titers as Compared With Baseline, as Measured by MN","description":"≥2-fold increase from baseline was defined as a ≥2 \\* LLOQ for participants with baseline undetectable antibody titer, or a 2-times or higher ratio in participants with pre-existing nAb titers. LLOQ=28.","timeFrame":"Days 8, 29, 36, and 57"},{"measure":"Percentage of Initially Seropositive Participants With a 4-Fold Increase in ZIKV-Specific nAb Titers as Compared With Baseline, as Measured by MN","description":"≥4-fold increase from baseline was defined as a ≥4 \\* LLOQ for participants with baseline undetectable antibody titer, or a 4-times or higher ratio in participants with pre-existing nAb titers. LLOQ=28.","timeFrame":"Days 8, 29, 36, and 57"}],"otherOutcomes":[{"measure":"Number of Deaths Related to Study Drug","description":"A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, irrespective of its perceived relationship to the study drug. The Investigator assessed the causality by determining whether there was a reasonable possibility that the death was related to the study drug, using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable.","timeFrame":"Day 1 through Day 196 for Main Study and Day 197 through Day 700 for Extension Period"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Understands and agrees to comply with the study procedures and provides written informed consent.\n* According to investigator assessment, is in good general health and can comply with study procedures.\n* Female participants of childbearing potential may be enrolled in the study if the participant: has a negative pregnancy test at the Eligibility Visit and on the day of the first investigational product (IP) injection; has practiced adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first IP injection; has agreed to continue adequate contraception through 3 months following the last IP injection; and is not currently breastfeeding.\n\nKey Exclusion Criteria:\n\n* Participant is acutely ill or febrile (temperature ≥38.0°Celsius/100.4°Farenheight) on the day of the first or second vaccination.\n* Participant had prior administration of a ZIKV vaccine candidate during a clinical study investigation.\n* Participant had prior administration of a marketed dengue vaccine or dengue vaccine candidate under clinical study investigation.\n* Participant has a body mass index (BMI) from ≤18 or ≥35 kilograms (kg)/square meter (m\\^2).\n* Participant has a history of myocarditis, pericarditis, or myopericarditis.\n* Participant has a history of a diagnosis or condition that, in the judgement of the investigator, is clinically unstable or may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures. \"Clinically unstable\" is defined as a diagnosis or condition requiring significant changes in management or medication within the 2 months prior to screening and includes ongoing work-up of an undiagnosed illness that could lead to a new diagnosis or condition.\n* Participant has any medical, psychiatric, or occupational condition, including reported history of drug or alcohol abuse, that in the opinion of the investigator, might pose a risk due to participation in the study or could interfere with the interpretation of study results.\n* Participant has as a history of anaphylaxis, urticaria, or other significant AR requiring medical intervention after receipt of a vaccine, including an mRNA vaccine or any components of an mRNA vaccine.\n* Participant has received or plans to receive a nonstudy vaccine (including authorized or approved vaccines for the prevention of COVID-19) ≤28 days prior to the first IP injection or within 28 days prior to or after any IP injection. Licensed influenza vaccine received within 14 days prior to the first IP injection or plans to receive a licensed influenza vaccine 14 days prior to through 14 days following each IP injection are not exclusionary.\n* Participant has received systemic immunoglobulins or blood products within 3 months prior to the day of enrollment.\n* Participant has donated ≥450 milliliters (mL) of blood products within 28 days of the Day 1 Visit.\n* Participant has participated in an interventional clinical study within 28 days prior to the day of enrollment or plans to do so while enrolled in this study.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Meridian Clinical Research (Sioux City, IA)","city":"Sioux City","state":"Iowa","zip":"51106","country":"United States","geoPoint":{"lat":42.49999,"lon":-96.40031}},{"facility":"Johnson County Clin-Trials","city":"Lenexa","state":"Kansas","zip":"66219","country":"United States","geoPoint":{"lat":38.95362,"lon":-94.73357}},{"facility":"Benchmark Research - Fort Worth","city":"Fort Worth","state":"Texas","zip":"76135","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"facility":"Clinical Research Puerto Rico, Inc.","city":"Guayama","state":"PR","zip":"00784","country":"Puerto Rico","geoPoint":{"lat":17.98413,"lon":-66.11378}},{"facility":"Ponce Medical School Foundation, Inc.","city":"Ponce","state":"PR","zip":"00713","country":"Puerto Rico","geoPoint":{"lat":18.01031,"lon":-66.62398}},{"facility":"Ponce Medical School Foundation, Inc.","city":"Ponce","state":"PR","zip":"00716","country":"Puerto Rico","geoPoint":{"lat":18.01031,"lon":-66.62398}},{"facility":"Clinical Research Puerto Rico, Inc.","city":"San Juan","state":"PR","zip":"00909","country":"Puerto Rico","geoPoint":{"lat":18.46633,"lon":-66.10572}},{"facility":"Latin Clinical Trial Center, Inc.","city":"San Juan","state":"PR","zip":"00909","country":"Puerto Rico","geoPoint":{"lat":18.46633,"lon":-66.10572}},{"facility":"GCM Medical Group, PSC","city":"San Juan","state":"PR","zip":"00917","country":"Puerto Rico","geoPoint":{"lat":18.46633,"lon":-66.10572}},{"facility":"Carribean Medical Research","city":"San Juan","state":"PR","zip":"00918","country":"Puerto Rico","geoPoint":{"lat":18.46633,"lon":-66.10572}},{"facility":"University of Puerto Rico","city":"San Juan","state":"PR","zip":"00935","country":"Puerto Rico","geoPoint":{"lat":18.46633,"lon":-66.10572}}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 808 participants were enrolled. One participant was randomized at two sites and received two injections. This participant was not presented under Per-Protocol Set but kept in Full Analysis Set, Safety Set, and Solicited Safety Set. This participant was discontinued from the study at one site upon the discovery of the duplicate participation and the incident was documented.","groups":[{"id":"FG000","title":"Placebo","description":"Participants received placebo matched to mRNA-1893 administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"FG001","title":"mRNA-1893 Low Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"FG002","title":"mRNA-1893 High Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"FG003","title":"mRNA-1893 High Dose (1-Dose Regimen)","description":"Participants received placebo matched to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There was 28-day interval between vaccinations."}],"periods":[{"title":"Main Study (196 Days)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"203"},{"groupId":"FG001","numSubjects":"201"},{"groupId":"FG002","numSubjects":"203"},{"groupId":"FG003","numSubjects":"201"}]},{"type":"Received First Injection","achievements":[{"groupId":"FG000","numSubjects":"201"},{"groupId":"FG001","numSubjects":"201"},{"groupId":"FG002","numSubjects":"202"},{"groupId":"FG003","numSubjects":"198"}]},{"type":"Received Second Injection","achievements":[{"groupId":"FG000","numSubjects":"187"},{"groupId":"FG001","numSubjects":"188"},{"groupId":"FG002","numSubjects":"187"},{"groupId":"FG003","numSubjects":"191"}]},{"type":"Randomized at Second Site","comment":"Randomized to mRNA-1893 High Dose (2-Dose Regimen) and then mRNA-1893 Low Dose (2-Dose Regimen)","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"173"},{"groupId":"FG001","numSubjects":"166"},{"groupId":"FG002","numSubjects":"176"},{"groupId":"FG003","numSubjects":"178"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"30"},{"groupId":"FG001","numSubjects":"35"},{"groupId":"FG002","numSubjects":"27"},{"groupId":"FG003","numSubjects":"23"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"26"},{"groupId":"FG002","numSubjects":"20"},{"groupId":"FG003","numSubjects":"11"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Pregnancy","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"8"}]},{"type":"Other Than Specified","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"2"}]}]},{"title":"Extension Period (Day 197 to Day 700)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"113"},{"groupId":"FG001","numSubjects":"109"},{"groupId":"FG002","numSubjects":"104"},{"groupId":"FG003","numSubjects":"116"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"97"},{"groupId":"FG001","numSubjects":"96"},{"groupId":"FG002","numSubjects":"89"},{"groupId":"FG003","numSubjects":"93"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"15"},{"groupId":"FG003","numSubjects":"23"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"11"}]},{"type":"Pregnancy","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"8"},{"groupId":"FG003","numSubjects":"10"}]},{"type":"Other Than Specified","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"The Safety Set included all participants who were randomized and received any study injection. One participant who was randomized at two sites and received two injections, has been included only once here for reporting the 'Baseline Characteristics' data. This participant was kept in both arms (Randomized to mRNA-1893 High Dose \\[2-Dose Regimen\\] and mRNA-1893 Low Dose \\[2-Dose Regimen\\]) in Full Analysis Set, Safety Set, and Solicited Safety Set for collection and reporting data.","groups":[{"id":"BG000","title":"Placebo","description":"Participants received placebo matched to mRNA-1893 administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"BG001","title":"mRNA-1893 Low Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"BG002","title":"mRNA-1893 High Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"BG003","title":"mRNA-1893 High Dose (1-Dose Regimen) (","description":"Participants received placebo matched to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There was 28-day interval between vaccinations."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"201"},{"groupId":"BG001","value":"201"},{"groupId":"BG002","value":"202"},{"groupId":"BG003","value":"198"},{"groupId":"BG004","value":"802"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"201"},{"groupId":"BG001","value":"201"},{"groupId":"BG002","value":"202"},{"groupId":"BG003","value":"198"},{"groupId":"BG004","value":"802"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"111"},{"groupId":"BG001","value":"119"},{"groupId":"BG002","value":"119"},{"groupId":"BG003","value":"114"},{"groupId":"BG004","value":"463"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"90"},{"groupId":"BG001","value":"82"},{"groupId":"BG002","value":"83"},{"groupId":"BG003","value":"84"},{"groupId":"BG004","value":"339"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"106"},{"groupId":"BG001","value":"106"},{"groupId":"BG002","value":"110"},{"groupId":"BG003","value":"107"},{"groupId":"BG004","value":"429"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"94"},{"groupId":"BG001","value":"94"},{"groupId":"BG002","value":"91"},{"groupId":"BG003","value":"90"},{"groupId":"BG004","value":"369"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"4"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Race","categories":[{"title":"White","measurements":[{"groupId":"BG000","value":"167"},{"groupId":"BG001","value":"167"},{"groupId":"BG002","value":"174"},{"groupId":"BG003","value":"172"},{"groupId":"BG004","value":"680"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"22"},{"groupId":"BG003","value":"21"},{"groupId":"BG004","value":"96"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"5"}]},{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"7"}]},{"title":"Native Hawaiian or other Pacific Islander","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}]},{"title":"Multiracial","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"7"}]},{"title":"Other","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"5"}]},{"title":"Not reported","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}]}]}]},{"title":"Seroresponse","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Flavivirus Seronegative Participants","measurements":[{"groupId":"BG000","value":"96"},{"groupId":"BG001","value":"92"},{"groupId":"BG002","value":"105"},{"groupId":"BG003","value":"111"},{"groupId":"BG004","value":"404"}]},{"title":"Flavivirus Seropositive Participants","measurements":[{"groupId":"BG000","value":"102"},{"groupId":"BG001","value":"103"},{"groupId":"BG002","value":"94"},{"groupId":"BG003","value":"82"},{"groupId":"BG004","value":"381"}]},{"title":"Missing","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"17"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)","description":"Solicited ARs (local and systemic) were collected in the electronic diary. Local ARs included: pain, erythema (redness), swelling/induration (hardness). Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, body temperature (potentially fever), and chills. A summary of all serious adverse events (SAEs) and all nonserious adverse events (AEs) (\"Other\"), regardless of causality, is in Reported \"Adverse Events\" section.","populationDescription":"The Solicited Safety Set included all participants who were randomized, received any study injection, and contributed with any solicited AR data. One participant who was randomized at two sites and received two injections was kept in both arms (Randomized to mRNA-1893 High Dose \\[2-Dose Regimen\\] and mRNA-1893 Low Dose \\[2-Dose Regimen\\]) in Solicited Safety Set for collection and reporting data.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 7 days post-vaccination","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to mRNA-1893 administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG001","title":"mRNA-1893 Low Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG002","title":"mRNA-1893 High Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG003","title":"mRNA-1893 High Dose (1-Dose Regimen)","description":"Participants received placebo matched to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There was 28-day interval between vaccinations."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"201"},{"groupId":"OG002","value":"201"},{"groupId":"OG003","value":"198"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"164"},{"groupId":"OG002","value":"183"},{"groupId":"OG003","value":"163"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Unsolicited Adverse Events (AEs)","description":"An unsolicited AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Unsolicited AEs were AEs that were not included in the protocol-defined solicited ARs. A treatment-emergent adverse event (TEAE) was defined as any AE not present before exposure to vaccine or any AE already present that worsened in intensity or frequency after exposure. A summary of all SAEs and all nonserious AEs (\"Other\"), regardless of causality, is located in the Reported \"Adverse Events\" section.","populationDescription":"The Safety Set included all participants who were randomized and received any study injection. One participant who was randomized at two sites and received two injections was kept in both arms (Randomized to mRNA-1893 High Dose \\[2-Dose Regimen\\] and mRNA-1893 Low Dose \\[2-Dose Regimen\\]) in Safety Set for collection and reporting data.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 28 days post-vaccination","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to mRNA-1893 administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG001","title":"mRNA-1893 Low Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG002","title":"mRNA-1893 High Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG003","title":"mRNA-1893 High Dose (1-Dose Regimen)","description":"Participants received placebo matched to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There was 28-day interval between vaccinations."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"201"},{"groupId":"OG001","value":"202"},{"groupId":"OG002","value":"202"},{"groupId":"OG003","value":"198"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"47"},{"groupId":"OG002","value":"52"},{"groupId":"OG003","value":"45"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Serious Adverse Events (SAEs), AEs of Special Interest (AESIs)","description":"An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, was a congenital anomaly/birth defect, or was an important medical event. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor were required. A summary of all SAEs and all nonserious AEs (\"Other\"), regardless of causality, is located in the Reported \"Adverse Events\" section.","populationDescription":"The Safety Set included all participants who were randomized and received any study injection. One participant who was randomized at two sites and received two injections was kept in both arms (Randomized to mRNA-1893 High Dose \\[2-Dose Regimen\\] and mRNA-1893 Low Dose \\[2-Dose Regimen\\]) in Safety Set for collection and reporting data.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 through Day 196 for Main Study and Day 197 through Day 700 for Extension Period","groups":[{"id":"OG000","title":"Main Study: Placebo","description":"Participants received placebo matched to mRNA-1893 administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG001","title":"Main Study: mRNA-1893 Low Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG002","title":"Main Study: mRNA-1893 High Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG003","title":"Main Study: mRNA-1893 High Dose (1-Dose Regimen)","description":"Participants received placebo matched to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There was 28-day interval between vaccinations."},{"id":"OG004","title":"Extension Period: Placebo","description":"Participants were followed up for up to Day 700 in the extension period."},{"id":"OG005","title":"Extension Period: mRNA-1893 Low Dose (2-Dose Regimen)","description":"Participants were followed up for up to Day 700 in the extension period."},{"id":"OG006","title":"Extension Period: mRNA-1893 High Dose (2-Dose Regimen)","description":"Participants were followed up for up to Day 700 in the extension period."},{"id":"OG007","title":"Extension Period: mRNA-1893 High Dose (1-Dose Regimen)","description":"Participants were followed up for up to Day 700 in the extension period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"201"},{"groupId":"OG001","value":"202"},{"groupId":"OG002","value":"202"},{"groupId":"OG003","value":"198"},{"groupId":"OG004","value":"113"},{"groupId":"OG005","value":"109"},{"groupId":"OG006","value":"104"},{"groupId":"OG007","value":"116"}]}],"classes":[{"title":"SAEs","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"7"}]}]},{"title":"AESIs","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Medically Attended AEs (MAAEs)","description":"An MAAE was an AE that led to an unscheduled visit to a healthcare practitioner. Note that the generation of the tables for the MAAE data for the Main Study occurred after the start of the Extension Period. Therefore, some of the MAAE data for this outcome measure may appear both in the Main Study and the Extension Period. A summary of all SAEs and all nonserious AEs (\"Other\"), regardless of causality, is located in the Reported \"Adverse Events\" section.","populationDescription":"The Safety Set included all participants who were randomized and received any study injection. One participant who was randomized at two sites and received two injections was kept in both arms (Randomized to mRNA-1893 High Dose \\[2-Dose Regimen\\] and mRNA-1893 Low Dose \\[2-Dose Regimen\\]) in Safety Set for collection and reporting data.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 through Day 196 for Main Study and Day 197 through Day 700 for Extension Period","groups":[{"id":"OG000","title":"Main Study: Placebo","description":"Participants received placebo matched to mRNA-1893 administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG001","title":"Main Study: mRNA-1893 Low Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG002","title":"Main Study: mRNA-1893 High Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG003","title":"Main Study: mRNA-1893 High Dose (1-Dose Regimen)","description":"Participants received placebo matched to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There was 28-day interval between vaccinations."},{"id":"OG004","title":"Extension Period: Placebo","description":"Participants were followed up for up to Day 700 in the extension period."},{"id":"OG005","title":"Extension Period: mRNA-1893 Low Dose (2-Dose Regimen)","description":"Participants were followed up for up to Day 700 in the extension period."},{"id":"OG006","title":"Extension Period: mRNA-1893 High Dose (2-Dose Regimen)","description":"Participants were followed up for up to Day 700 in the extension period."},{"id":"OG007","title":"Extension Period: mRNA-1893 High Dose (1-Dose Regimen)","description":"Participants were followed up for up to Day 700 in the extension period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"201"},{"groupId":"OG001","value":"202"},{"groupId":"OG002","value":"202"},{"groupId":"OG003","value":"198"},{"groupId":"OG004","value":"113"},{"groupId":"OG005","value":"109"},{"groupId":"OG006","value":"104"},{"groupId":"OG007","value":"116"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"62"},{"groupId":"OG003","value":"63"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"24"},{"groupId":"OG006","value":"30"},{"groupId":"OG007","value":"31"}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titer (GMT) of Zika Virus (ZIKV)-Specific Neutralizing Antibodies (nAbs) at Day 57, as Measured by 50% Plaque Reduction Neutralization Test (PRNT50)","description":"Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5 \\* LLOQ. Values that were greater than the upper limit of quantification (ULOQ) were converted to the ULOQ. LLOQ=91; ULOQ=24814. 95% confidence interval (CI) was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation.","populationDescription":"The Per-Protocol Set for Antibody-Mediated Immunogenicity (PPAMI) included all participants who received any study injection, who did not have major protocol deviations that impacted AMI response, and who complied with the injection schedule and the timing of immunogenicity blood sampling to have post-injection results available for at least 1 assay component of AMI at the corresponding visit. Here, 'Number analyzed' = participants evaluable for specified categories.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Day 57","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to mRNA-1893 administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG001","title":"mRNA-1893 Low Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG002","title":"mRNA-1893 High Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG003","title":"mRNA-1893 High Dose (1-Dose Regimen)","description":"Participants received placebo matched to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There was 28-day interval between vaccinations."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"classes":[{"title":"All Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"61.06","lowerLimit":"54.07","upperLimit":"68.96"},{"groupId":"OG001","value":"427.53","lowerLimit":"343.28","upperLimit":"532.45"},{"groupId":"OG002","value":"434.92","lowerLimit":"343.63","upperLimit":"550.46"},{"groupId":"OG003","value":"163.28","lowerLimit":"122.68","upperLimit":"217.30"}]}]},{"title":"Flavivirus-seronegative Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"45.50","lowerLimit":"NA","upperLimit":"NA","comment":"Due to not enough variability in the values, the CI (upper and lower limit) could not be calculated."},{"groupId":"OG001","value":"327.95","lowerLimit":"246.98","upperLimit":"435.47"},{"groupId":"OG002","value":"363.03","lowerLimit":"277.84","upperLimit":"474.35"},{"groupId":"OG003","value":"68.96","lowerLimit":"55.94","upperLimit":"85.02"}]}]},{"title":"Flavivirus-seropositive Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"79.46","lowerLimit":"63.92","upperLimit":"98.78"},{"groupId":"OG001","value":"539.17","lowerLimit":"385.76","upperLimit":"753.59"},{"groupId":"OG002","value":"502.11","lowerLimit":"337.76","upperLimit":"746.45"},{"groupId":"OG003","value":"558.49","lowerLimit":"336.21","upperLimit":"927.73"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Geometric Mean Ratio (GMR)","paramValue":"7.002","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"5.451","ciUpperLimit":"8.992","estimateComment":"GMR (mRNA-1893 Low Dose \\[2-Dose Regimen\\] vs. Placebo) for all participants"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","paramType":"GMR","paramValue":"7.123","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"5.467","ciUpperLimit":"9.279","estimateComment":"GMR (mRNA-1893 High Dose \\[2-Dose Regimen\\] vs. Placebo) for all participants"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"OTHER","paramType":"GMR","paramValue":"2.674","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.961","ciUpperLimit":"3.646","estimateComment":"GMR (mRNA-1893 High Dose \\[1-Dose Regimen\\] vs. Placebo) for all participants"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"GMR","paramValue":"7.208","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"5.428","ciUpperLimit":"9.571","estimateComment":"GMR (mRNA-1893 Low Dose \\[2-Dose Regimen\\] vs. Placebo) for flavivirus-seronegative participants"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","paramType":"GMR","paramValue":"7.979","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"6.106","ciUpperLimit":"10.425","estimateComment":"GMR (mRNA-1893 High Dose \\[2-Dose Regimen\\] vs. Placebo) for flavivirus-seronegative participants"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"OTHER","paramType":"GMR","paramValue":"1.516","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.229","ciUpperLimit":"1.869","estimateComment":"GMR (mRNA-1893 High Dose \\[1-Dose Regimen\\] vs. Placebo) for flavivirus-seronegative participants"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"GMR","paramValue":"6.785","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"4.562","ciUpperLimit":"10.092","estimateComment":"GMR (mRNA-1893 Low Dose \\[2-Dose Regimen\\] vs. Placebo) for flavivirus-seropositive participants"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","paramType":"GMR","paramValue":"6.319","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"4.030","ciUpperLimit":"9.909","estimateComment":"GMR (mRNA-1893 High Dose \\[2-Dose Regimen\\] vs. Placebo) for flavivirus-seropositive participants"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"OTHER","paramType":"GMR","paramValue":"7.028","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"4.056","ciUpperLimit":"12.180","estimateComment":"GMR (mRNA-1893 High Dose \\[1-Dose Regimen\\] vs. Placebo) for flavivirus-seropositive participants"}]},{"type":"PRIMARY","title":"GMT of ZIKV-specific nAbs at Day 57, as Measured by 80% Plaque Reduction Neutralization Test (PRNT80)","description":"Antibody values reported as below the LLOQ were replaced by 0.5 \\* LLOQ. Values that were greater than the ULOQ were converted to the ULOQ. LLOQ=91; ULOQ=24814. 95% CI was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation.","populationDescription":"The PPAMI included all participants who received any study injection, who did not have major protocol deviations that impacted AMI response, and who complied with the injection schedule and the timing of immunogenicity blood sampling to have post-injection results available for at least 1 assay component of AMI at the corresponding visit. Here, 'Number analyzed' = participants evaluable for specified categories.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Day 57","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to mRNA-1893 administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG001","title":"mRNA-1893 Low Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG002","title":"mRNA-1893 High Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG003","title":"mRNA-1893 High Dose (1-Dose Regimen)","description":"Participants received placebo matched to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There was 28-day interval between vaccinations."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"classes":[{"title":"All Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.80","lowerLimit":"18.60","upperLimit":"23.26"},{"groupId":"OG001","value":"110.52","lowerLimit":"88.59","upperLimit":"137.88"},{"groupId":"OG002","value":"111.21","lowerLimit":"88.04","upperLimit":"140.48"},{"groupId":"OG003","value":"48.36","lowerLimit":"36.56","upperLimit":"63.97"}]}]},{"title":"Flavivirus-seronegative Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.50","lowerLimit":"NA","upperLimit":"NA","comment":"Due to not enough variability in the values, the CI (upper and lower limit) could not be calculated."},{"groupId":"OG001","value":"69.64","lowerLimit":"54.81","upperLimit":"88.48"},{"groupId":"OG002","value":"87.45","lowerLimit":"70.01","upperLimit":"109.24"},{"groupId":"OG003","value":"19.89","lowerLimit":"17.05","upperLimit":"23.21"}]}]},{"title":"Flavivirus-seropositive Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.60","lowerLimit":"20.88","upperLimit":"31.38"},{"groupId":"OG001","value":"166.23","lowerLimit":"117.69","upperLimit":"234.80"},{"groupId":"OG002","value":"139.57","lowerLimit":"91.83","upperLimit":"212.13"},{"groupId":"OG003","value":"174.18","lowerLimit":"104.33","upperLimit":"290.79"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"GMR","paramValue":"5.312","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"4.149","ciUpperLimit":"6.802","estimateComment":"GMR (mRNA-1893 Low Dose \\[2-Dose Regimen\\] vs. Placebo) for all participants"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","paramType":"GMR","paramValue":"5.346","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"4.128","ciUpperLimit":"6.922","estimateComment":"GMR (mRNA-1893 High Dose \\[2-Dose Regimen\\] vs. Placebo) for all participants"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"OTHER","paramType":"GMR","paramValue":"2.325","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.721","ciUpperLimit":"3.140","estimateComment":"GMR (mRNA-1893 High Dose \\[1-Dose Regimen\\] vs. Placebo) for all participants"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"GMR","paramValue":"4.221","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.322","ciUpperLimit":"5.363","estimateComment":"GMR (mRNA-1893 Low Dose \\[2-Dose Regimen\\] vs. Placebo) for flavivirus-negative participants"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","paramType":"GMR","paramValue":"5.300","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"4.243","ciUpperLimit":"6.620","estimateComment":"GMR (mRNA-1893 High Dose \\[2-Dose Regimen\\] vs. Placebo) for flavivirus-negative participants"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"OTHER","paramType":"GMR","paramValue":"1.206","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.033","ciUpperLimit":"1.407","estimateComment":"GMR (mRNA-1893 High Dose \\[1-Dose Regimen\\] vs. Placebo) for flavivirus-negative participants"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"GMR","paramValue":"6.493","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"4.358","ciUpperLimit":"9.674","estimateComment":"GMR (mRNA-1893 Low Dose \\[2-Dose Regimen\\] vs. Placebo) for flavivirus-positive participants"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","paramType":"GMR","paramValue":"5.452","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.430","ciUpperLimit":"8.665","estimateComment":"GMR (mRNA-1893 High Dose \\[2-Dose Regimen\\] vs. Placebo) for flavivirus-positive participants"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"OTHER","paramType":"GMR","paramValue":"6.804","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.928","ciUpperLimit":"11.784","estimateComment":"GMR (mRNA-1893 High Dose \\[1-Dose Regimen\\] vs. Placebo) for flavivirus-positive participants"}]},{"type":"PRIMARY","title":"Percentage of Participants With Seroconversion at Day 57, as Measured by PRNT50","description":"Seroconversion was defined as an increase in ZIKV-specific nAb titer from below the LLOQ to a titer equal to or above LLOQ, or an increase of at least 4-fold in ZIKV-specific nAb titer in participants with pre-existing nAb titers. LLOQ=91; ULOQ=24814.","populationDescription":"The PPAMI included all participants who received any study injection, who did not have major protocol deviations that impacted AMI response, and who complied with the injection schedule and the timing of immunogenicity blood sampling to have post-injection results available for at least 1 assay component of AMI at the corresponding visit. Here, 'Number analyzed' = participants evaluable for specified categories.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 57","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to mRNA-1893 administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG001","title":"mRNA-1893 Low Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG002","title":"mRNA-1893 High Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG003","title":"mRNA-1893 High Dose (1-Dose Regimen)","description":"Participants received placebo matched to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There was 28-day interval between vaccinations."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"classes":[{"title":"All Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","lowerLimit":"1.74","upperLimit":"8.65"},{"groupId":"OG001","value":"81.0","lowerLimit":"74.10","upperLimit":"86.70"},{"groupId":"OG002","value":"82.1","lowerLimit":"75.31","upperLimit":"87.67"},{"groupId":"OG003","value":"39.9","lowerLimit":"32.30","upperLimit":"47.83"}]}]},{"title":"Flavivirus-seronegative Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.00","upperLimit":"4.74"},{"groupId":"OG001","value":"86.1","lowerLimit":"75.94","upperLimit":"93.13"},{"groupId":"OG002","value":"87.7","lowerLimit":"78.47","upperLimit":"93.92"},{"groupId":"OG003","value":"20.4","lowerLimit":"12.77","upperLimit":"30.05"}]}]},{"title":"Flavivirus-seropositive Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","lowerLimit":"3.34","upperLimit":"16.05"},{"groupId":"OG001","value":"75.9","lowerLimit":"65.50","upperLimit":"84.40"},{"groupId":"OG002","value":"75.9","lowerLimit":"65.02","upperLimit":"84.86"},{"groupId":"OG003","value":"65.7","lowerLimit":"53.06","upperLimit":"76.85"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"percentage difference","paramValue":"76.69","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"69.10","ciUpperLimit":"82.68","estimateComment":"Percentage Difference (mRNA-1893 Low Dose \\[2-Dose Regimen\\] vs. Placebo) for all participants"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","paramType":"percentage difference","paramValue":"77.80","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"70.29","ciUpperLimit":"83.67","estimateComment":"Percentage Difference (mRNA-1893 High Dose \\[2-Dose Regimen\\] vs. Placebo) for all participants"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"OTHER","paramType":"percentage difference","paramValue":"35.58","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"27.47","ciUpperLimit":"43.74","estimateComment":"Percentage Difference (mRNA-1893 High Dose \\[1-Dose Regimen\\] vs. Placebo) for all participants"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"percentage difference","paramValue":"86.11","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"76.25","ciUpperLimit":"92.29","estimateComment":"Percentage Difference (mRNA-1893 Low Dose \\[2-Dose Regimen\\] vs. Placebo) for flavivirus-negative participants"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","paramType":"percentage difference","paramValue":"87.65","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"78.71","ciUpperLimit":"93.17","estimateComment":"Percentage Difference (mRNA-1893 High Dose \\[2-Dose Regimen\\] vs. Placebo) for flavivirus-negative participants"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"OTHER","paramType":"percentage difference","paramValue":"20.43","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"13.47","ciUpperLimit":"29.75","estimateComment":"Percentage Difference (mRNA-1893 High Dose \\[1-Dose Regimen\\] vs. Placebo) for flavivirus-negative participants"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"percentage difference","paramValue":"67.72","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"55.69","ciUpperLimit":"77.07","estimateComment":"Percentage Difference (mRNA-1893 Low Dose \\[2-Dose Regimen\\] vs. Placebo) for flavivirus-positive participants"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","paramType":"percentage difference","paramValue":"67.81","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"55.36","ciUpperLimit":"77.44","estimateComment":"Percentage Difference (mRNA-1893 High Dose \\[2-Dose Regimen\\] vs. Placebo) for flavivirus-positive participants"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"OTHER","paramType":"percentage difference","paramValue":"57.53","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"43.81","ciUpperLimit":"69.08","estimateComment":"Percentage Difference (mRNA-1893 High Dose \\[1-Dose Regimen\\] vs. Placebo) for flavivirus-positive participants"}]},{"type":"PRIMARY","title":"Percentage of Participants With Seroconversion at Day 57, as Measured by PRNT80","description":"Seroconversion was defined as an increase in ZIKV-specific nAb titer from below the LLOQ to a titer equal to or above LLOQ, or an increase of at least 4-fold in ZIKV-specific nAb titer in participants with pre-existing nAb titers. LLOQ=91; ULOQ=24814.","populationDescription":"The PPAMI included all participants who received any study injection, who did not have major protocol deviations that impacted AMI response, and who complied with the injection schedule and the timing of immunogenicity blood sampling to have post-injection results available for at least 1 assay component of AMI at the corresponding visit. Here, 'Number analyzed' = participants evaluable for specified categories.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 57","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to mRNA-1893 administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG001","title":"mRNA-1893 Low Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG002","title":"mRNA-1893 High Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG003","title":"mRNA-1893 High Dose (1-Dose Regimen)","description":"Participants received placebo matched to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There was 28-day interval between vaccinations."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"classes":[{"title":"All Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"0.15","upperLimit":"4.36"},{"groupId":"OG001","value":"76.7","lowerLimit":"69.43","upperLimit":"82.94"},{"groupId":"OG002","value":"76.5","lowerLimit":"69.25","upperLimit":"82.83"},{"groupId":"OG003","value":"32.5","lowerLimit":"25.40","upperLimit":"40.28"}]}]},{"title":"Flavivirus-seronegative Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.00","upperLimit":"4.74"},{"groupId":"OG001","value":"77.8","lowerLimit":"66.44","upperLimit":"86.73"},{"groupId":"OG002","value":"82.7","lowerLimit":"72.70","upperLimit":"90.22"},{"groupId":"OG003","value":"9.7","lowerLimit":"4.52","upperLimit":"17.58"}]}]},{"title":"Flavivirus-seropositive Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","lowerLimit":"0.28","upperLimit":"8.15"},{"groupId":"OG001","value":"74.7","lowerLimit":"64.25","upperLimit":"83.42"},{"groupId":"OG002","value":"69.6","lowerLimit":"58.25","upperLimit":"79.47"},{"groupId":"OG003","value":"65.7","lowerLimit":"53.06","upperLimit":"76.85"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"percentage difference","paramValue":"75.46","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"68.12","ciUpperLimit":"81.49","estimateComment":"Percentage Difference (mRNA-1893 Low Dose \\[2-Dose Regimen\\] vs. Placebo) for all participants"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","paramType":"percentage difference","paramValue":"75.32","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"67.94","ciUpperLimit":"81.38","estimateComment":"Percentage Difference (mRNA-1893 High Dose \\[2-Dose Regimen\\] vs. Placebo) for all participants"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"OTHER","paramType":"percentage difference","paramValue":"31.29","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"24.23","ciUpperLimit":"38.96","estimateComment":"Percentage Difference (mRNA-1893 High Dose \\[1-Dose Regimen\\] vs. Placebo) for all participants"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"percentage difference","paramValue":"77.78","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"66.87","ciUpperLimit":"85.85","estimateComment":"Percentage Difference (mRNA-1893 Low Dose \\[2-Dose Regimen\\] vs. Placebo) for flavivirus-negative participants"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","paramType":"percentage difference","paramValue":"82.72","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"73.02","ciUpperLimit":"89.43","estimateComment":"Percentage Difference (mRNA-1893 High Dose \\[2-Dose Regimen\\] vs. Placebo) for flavivirus-negative participants"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"OTHER","paramType":"percentage difference","paramValue":"9.68","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"4.63","ciUpperLimit":"17.41","estimateComment":"Percentage Difference (mRNA-1893 High Dose \\[1-Dose Regimen\\] vs. Placebo) for flavivirus-negative participants"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"percentage difference","paramValue":"72.39","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"61.56","ciUpperLimit":"80.83","estimateComment":"Percentage Difference (mRNA-1893 Low Dose \\[2-Dose Regimen\\] vs. Placebo) for flavivirus-positive participants"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","paramType":"percentage difference","paramValue":"67.29","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"55.72","ciUpperLimit":"76.78","estimateComment":"Percentage Difference (mRNA-1893 High Dose \\[2-Dose Regimen\\] vs. Placebo) for flavivirus-positive participants"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"OTHER","paramType":"percentage difference","paramValue":"63.35","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"50.75","ciUpperLimit":"74.00","estimateComment":"Percentage Difference (mRNA-1893 High Dose \\[1-Dose Regimen\\] vs. Placebo) for flavivirus-positive participants"}]},{"type":"SECONDARY","title":"GMT of ZIKV-Specific nAbs at Days 1, 8, 29, and 36, as Measured by PRNT50 and PRNT80","description":"Antibody values reported as below the LLOQ were replaced by 0.5 \\* LLOQ. Values that were greater than the ULOQ were converted to the ULOQ. LLOQ=91; ULOQ=24814. 95% CI was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation.","populationDescription":"The PPAMI included all participants who received any study injection, who did not have major protocol deviations that impacted AMI response, and who complied with the injection schedule and the timing of immunogenicity blood sampling to have post-injection results available for at least 1 assay component of AMI at the corresponding visit. Here, 'Number analyzed' = participants evaluable for specified categories.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Days 1, 8, 29, and 36","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to mRNA-1893 administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG001","title":"mRNA-1893 Low Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG002","title":"mRNA-1893 High Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG003","title":"mRNA-1893 High Dose (1-Dose Regimen)","description":"Participants received placebo matched to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There was 28-day interval between vaccinations."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"classes":[{"title":"Day 1: All Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60.64","lowerLimit":"53.33","upperLimit":"68.95"},{"groupId":"OG001","value":"61.21","lowerLimit":"53.93","upperLimit":"69.46"},{"groupId":"OG002","value":"54.57","lowerLimit":"49.53","upperLimit":"60.13"},{"groupId":"OG003","value":"59.41","lowerLimit":"52.45","upperLimit":"67.29"}]}]},{"title":"Day 8: All Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"161"},{"groupId":"OG003","value":"162"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"62.15","lowerLimit":"54.37","upperLimit":"71.04"},{"groupId":"OG001","value":"116.92","lowerLimit":"90.06","upperLimit":"151.81"},{"groupId":"OG002","value":"105.78","lowerLimit":"80.71","upperLimit":"138.64"},{"groupId":"OG003","value":"57.98","lowerLimit":"51.17","upperLimit":"65.69"}]}]},{"title":"Day 29: All Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"162"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66.66","lowerLimit":"57.15","upperLimit":"77.76"},{"groupId":"OG001","value":"151.34","lowerLimit":"115.71","upperLimit":"197.94"},{"groupId":"OG002","value":"140.50","lowerLimit":"107.24","upperLimit":"184.08"},{"groupId":"OG003","value":"59.59","lowerLimit":"52.10","upperLimit":"68.15"}]}]},{"title":"Day 36: All Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"161"},{"groupId":"OG003","value":"162"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"58.51","lowerLimit":"52.16","upperLimit":"65.63"},{"groupId":"OG001","value":"493.59","lowerLimit":"382.88","upperLimit":"636.30"},{"groupId":"OG002","value":"412.24","lowerLimit":"316.08","upperLimit":"537.65"},{"groupId":"OG003","value":"118.04","lowerLimit":"89.84","upperLimit":"155.09"}]}]},{"title":"Day 1: Flavivirus-negative Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"45.50","lowerLimit":"NA","upperLimit":"NA","comment":"Due to not enough variability in the values, the CI (upper and lower limit) could not be calculated."},{"groupId":"OG001","value":"50.76","lowerLimit":"43.31","upperLimit":"59.49"},{"groupId":"OG002","value":"45.50","lowerLimit":"NA","upperLimit":"NA","comment":"Due to not enough variability in the values, the CI (upper and lower limit) could not be calculated."},{"groupId":"OG003","value":"48.58","lowerLimit":"44.97","upperLimit":"52.48"}]}]},{"title":"Day 8: Flavivirus-negative Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"45.50","lowerLimit":"NA","upperLimit":"NA","comment":"Due to not enough variability in the values, the CI (upper and lower limit) could not be calculated."},{"groupId":"OG001","value":"50.24","lowerLimit":"43.73","upperLimit":"57.71"},{"groupId":"OG002","value":"48.05","lowerLimit":"44.03","upperLimit":"52.43"},{"groupId":"OG003","value":"50.30","lowerLimit":"45.07","upperLimit":"56.15"}]}]},{"title":"Day 29: Flavivirus-negative Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"46.45","lowerLimit":"44.58","upperLimit":"48.39"},{"groupId":"OG001","value":"57.81","lowerLimit":"48.16","upperLimit":"69.40"},{"groupId":"OG002","value":"67.45","lowerLimit":"56.47","upperLimit":"80.56"},{"groupId":"OG003","value":"48.85","lowerLimit":"45.24","upperLimit":"52.75"}]}]},{"title":"Day 36: Flavivirus-negative Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"80"},{"groupId":"OG003","value":"92"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"45.50","lowerLimit":"NA","upperLimit":"NA","comment":"Due to not enough variability in the values, the CI (upper and lower limit) could not be calculated."},{"groupId":"OG001","value":"478.42","lowerLimit":"346.32","upperLimit":"660.91"},{"groupId":"OG002","value":"344.02","lowerLimit":"249.51","upperLimit":"474.33"},{"groupId":"OG003","value":"56.46","lowerLimit":"46.29","upperLimit":"68.86"}]}]},{"title":"Day 1: Flavivirus-positive Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"78.42","lowerLimit":"62.17","upperLimit":"98.91"},{"groupId":"OG001","value":"72.45","lowerLimit":"59.72","upperLimit":"87.88"},{"groupId":"OG002","value":"66.06","lowerLimit":"54.52","upperLimit":"80.03"},{"groupId":"OG003","value":"79.50","lowerLimit":"60.53","upperLimit":"104.40"}]}]},{"title":"Day 8: Flavivirus-positive Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"78"},{"groupId":"OG003","value":"66"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"81.87","lowerLimit":"64.46","upperLimit":"103.98"},{"groupId":"OG001","value":"245.67","lowerLimit":"161.42","upperLimit":"373.91"},{"groupId":"OG002","value":"245.31","lowerLimit":"150.29","upperLimit":"400.42"},{"groupId":"OG003","value":"71.60","lowerLimit":"55.17","upperLimit":"92.92"}]}]},{"title":"Day 29: Flavivirus-positive Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"92.15","lowerLimit":"70.05","upperLimit":"121.22"},{"groupId":"OG001","value":"350.77","lowerLimit":"234.46","upperLimit":"524.78"},{"groupId":"OG002","value":"295.81","lowerLimit":"184.73","upperLimit":"473.71"},{"groupId":"OG003","value":"79.46","lowerLimit":"58.87","upperLimit":"107.25"}]}]},{"title":"Day 36: Flavivirus-positive Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"73.48","lowerLimit":"59.61","upperLimit":"90.57"},{"groupId":"OG001","value":"507.03","lowerLimit":"340.84","upperLimit":"754.26"},{"groupId":"OG002","value":"487.78","lowerLimit":"315.43","upperLimit":"754.30"},{"groupId":"OG003","value":"339.16","lowerLimit":"203.88","upperLimit":"564.20"}]}]},{"title":"Day 1: All Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.06","lowerLimit":"18.82","upperLimit":"23.58"},{"groupId":"OG001","value":"21.23","lowerLimit":"19.13","upperLimit":"23.56"},{"groupId":"OG002","value":"18.94","lowerLimit":"17.56","upperLimit":"20.42"},{"groupId":"OG003","value":"19.60","lowerLimit":"17.84","upperLimit":"21.54"}]}]},{"title":"Day 8: All Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"161"},{"groupId":"OG003","value":"162"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.50","lowerLimit":"18.46","upperLimit":"22.77"},{"groupId":"OG001","value":"40.88","lowerLimit":"31.55","upperLimit":"52.97"},{"groupId":"OG002","value":"37.44","lowerLimit":"28.52","upperLimit":"49.16"},{"groupId":"OG003","value":"20.10","lowerLimit":"18.01","upperLimit":"22.42"}]}]},{"title":"Day 29: All Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"162"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.07","lowerLimit":"18.94","upperLimit":"23.44"},{"groupId":"OG001","value":"49.95","lowerLimit":"38.14","upperLimit":"65.42"},{"groupId":"OG002","value":"43.46","lowerLimit":"33.06","upperLimit":"57.13"},{"groupId":"OG003","value":"19.72","lowerLimit":"17.83","upperLimit":"21.82"}]}]},{"title":"Day 36: All Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"161"},{"groupId":"OG003","value":"162"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.40","lowerLimit":"18.42","upperLimit":"22.59"},{"groupId":"OG001","value":"124.30","lowerLimit":"97.25","upperLimit":"158.87"},{"groupId":"OG002","value":"121.27","lowerLimit":"93.24","upperLimit":"157.71"},{"groupId":"OG003","value":"39.69","lowerLimit":"30.34","upperLimit":"51.92"}]}]},{"title":"Day 1: Flavivirus-negative Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.50","lowerLimit":"NA","upperLimit":"NA","comment":"Due to not enough variability in the values, the CI (upper and lower limit) could not be calculated."},{"groupId":"OG001","value":"18.06","lowerLimit":"15.91","upperLimit":"20.49"},{"groupId":"OG002","value":"16.50","lowerLimit":"NA","upperLimit":"NA","comment":"Due to not enough variability in the values, the CI (upper and lower limit) could not be calculated."},{"groupId":"OG003","value":"17.63","lowerLimit":"16.28","upperLimit":"19.10"}]}]},{"title":"Day 8: Flavivirus-negative Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.50","lowerLimit":"NA","upperLimit":"NA","comment":"Due to not enough variability in the values, the CI (upper and lower limit) could not be calculated."},{"groupId":"OG001","value":"18.43","lowerLimit":"15.78","upperLimit":"21.52"},{"groupId":"OG002","value":"17.24","lowerLimit":"15.80","upperLimit":"18.81"},{"groupId":"OG003","value":"17.58","lowerLimit":"16.22","upperLimit":"19.05"}]}]},{"title":"Day 29: Flavivirus-negative Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.95","lowerLimit":"16.07","upperLimit":"17.88"},{"groupId":"OG001","value":"18.75","lowerLimit":"16.15","upperLimit":"21.75"},{"groupId":"OG002","value":"19.06","lowerLimit":"16.73","upperLimit":"21.72"},{"groupId":"OG003","value":"17.64","lowerLimit":"16.25","upperLimit":"19.15"}]}]},{"title":"Day 36: Flavivirus-negative Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"80"},{"groupId":"OG003","value":"92"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.50","lowerLimit":"NA","upperLimit":"NA","comment":"Due to not enough variability in the values, the CI (upper and lower limit) could not be calculated."},{"groupId":"OG001","value":"95.88","lowerLimit":"71.94","upperLimit":"127.78"},{"groupId":"OG002","value":"89.62","lowerLimit":"66.16","upperLimit":"121.40"},{"groupId":"OG003","value":"19.02","lowerLimit":"16.09","upperLimit":"22.48"}]}]},{"title":"Day 1: Flavivirus-positive Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.21","lowerLimit":"21.36","upperLimit":"32.16"},{"groupId":"OG001","value":"24.56","lowerLimit":"20.91","upperLimit":"28.85"},{"groupId":"OG002","value":"21.89","lowerLimit":"18.84","upperLimit":"25.42"},{"groupId":"OG003","value":"22.89","lowerLimit":"18.78","upperLimit":"27.89"}]}]},{"title":"Day 8: Flavivirus-positive Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"78"},{"groupId":"OG003","value":"66"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24.84","lowerLimit":"20.54","upperLimit":"30.04"},{"groupId":"OG001","value":"82.41","lowerLimit":"54.22","upperLimit":"125.26"},{"groupId":"OG002","value":"85.57","lowerLimit":"52.06","upperLimit":"140.65"},{"groupId":"OG003","value":"24.49","lowerLimit":"19.27","upperLimit":"31.12"}]}]},{"title":"Day 29: Flavivirus-positive Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.61","lowerLimit":"21.21","upperLimit":"30.93"},{"groupId":"OG001","value":"116.95","lowerLimit":"77.36","upperLimit":"176.79"},{"groupId":"OG002","value":"99.92","lowerLimit":"61.83","upperLimit":"161.47"},{"groupId":"OG003","value":"23.21","lowerLimit":"18.71","upperLimit":"28.79"}]}]},{"title":"Day 36: Flavivirus-positive Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24.73","lowerLimit":"20.52","upperLimit":"29.81"},{"groupId":"OG001","value":"156.24","lowerLimit":"105.60","upperLimit":"231.16"},{"groupId":"OG002","value":"161.96","lowerLimit":"104.84","upperLimit":"250.22"},{"groupId":"OG003","value":"113.38","lowerLimit":"67.59","upperLimit":"190.20"}]}]}]},{"type":"SECONDARY","title":"GMT of ZIKV-Specific nAbs at Days 1, 8, 29, 36, and 57, as Measured by Microneutralization (MN)","description":"Antibody values reported as below the LLOQ were replaced by 0.5 \\* LLOQ. Values that were greater than the ULOQ were converted to the ULOQ. LLOQ=28; ULOQ=11589. 95% CI was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation.","populationDescription":"The PPAMI included all participants who received any study injection, who did not have major protocol deviations that impacted AMI response, and who complied with the injection schedule and the timing of immunogenicity blood sampling to have post-injection results available for at least 1 assay component of AMI at the corresponding visit. Here, 'Number analyzed' = participants evaluable for specified categories.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Days 1, 8, 29, 36, and 57","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to mRNA-1893 administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG001","title":"mRNA-1893 Low Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG002","title":"mRNA-1893 High Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG003","title":"mRNA-1893 High Dose (1-Dose Regimen)","description":"Participants received placebo matched to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There was 28-day interval between vaccinations."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"classes":[{"title":"Day 1: All Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.54","lowerLimit":"24.08","upperLimit":"38.73"},{"groupId":"OG001","value":"32.98","lowerLimit":"26.18","upperLimit":"41.55"},{"groupId":"OG002","value":"25.31","lowerLimit":"20.43","upperLimit":"31.36"},{"groupId":"OG003","value":"27.94","lowerLimit":"22.45","upperLimit":"34.78"}]}]},{"title":"Day 8: All Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27.99","lowerLimit":"22.52","upperLimit":"34.80"},{"groupId":"OG001","value":"76.17","lowerLimit":"52.37","upperLimit":"110.79"},{"groupId":"OG002","value":"80.70","lowerLimit":"55.40","upperLimit":"117.55"},{"groupId":"OG003","value":"24.68","lowerLimit":"20.43","upperLimit":"29.80"}]}]},{"title":"Day 29: All Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"162"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"32.05","lowerLimit":"25.20","upperLimit":"40.75"},{"groupId":"OG001","value":"489.20","lowerLimit":"365.80","upperLimit":"654.24"},{"groupId":"OG002","value":"544.38","lowerLimit":"416.59","upperLimit":"711.36"},{"groupId":"OG003","value":"28.61","lowerLimit":"22.85","upperLimit":"35.83"}]}]},{"title":"Day 36: All Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"161"},{"groupId":"OG003","value":"162"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27.74","lowerLimit":"22.42","upperLimit":"34.32"},{"groupId":"OG001","value":"1318.97","lowerLimit":"1068.49","upperLimit":"1628.15"},{"groupId":"OG002","value":"1380.12","lowerLimit":"1109.40","upperLimit":"1716.91"},{"groupId":"OG003","value":"81.79","lowerLimit":"56.62","upperLimit":"118.15"}]}]},{"title":"Day 57: All Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.60","lowerLimit":"24.81","upperLimit":"40.24"},{"groupId":"OG001","value":"2261.02","lowerLimit":"1903.39","upperLimit":"2685.84"},{"groupId":"OG002","value":"2270.12","lowerLimit":"1907.12","upperLimit":"2702.22"},{"groupId":"OG003","value":"643.02","lowerLimit":"491.83","upperLimit":"840.67"}]}]},{"title":"Day 1: Flavivirus-negative Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.00","lowerLimit":"NA","upperLimit":"NA","comment":"Due to not enough variability in the values, the CI (upper and lower limit) could not be calculated."},{"groupId":"OG001","value":"16.25","lowerLimit":"13.69","upperLimit":"19.30"},{"groupId":"OG002","value":"14.00","lowerLimit":"NA","upperLimit":"NA","comment":"Due to not enough variability in the values, the CI (upper and lower limit) could not be calculated."},{"groupId":"OG003","value":"15.99","lowerLimit":"13.66","upperLimit":"18.72"}]}]},{"title":"Day 8: Flavivirus-negative Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.00","lowerLimit":"NA","upperLimit":"NA","comment":"Due to not enough variability in the values, the CI (upper and lower limit) could not be calculated."},{"groupId":"OG001","value":"17.73","lowerLimit":"13.79","upperLimit":"22.80"},{"groupId":"OG002","value":"20.22","lowerLimit":"16.32","upperLimit":"25.04"},{"groupId":"OG003","value":"15.66","lowerLimit":"13.76","upperLimit":"17.82"}]}]},{"title":"Day 29: Flavivirus-negative Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.00","lowerLimit":"NA","upperLimit":"NA","comment":"Due to not enough variability in the values, the CI (upper and lower limit) could not be calculated."},{"groupId":"OG001","value":"200.15","lowerLimit":"148.92","upperLimit":"268.99"},{"groupId":"OG002","value":"285.93","lowerLimit":"211.77","upperLimit":"386.07"},{"groupId":"OG003","value":"16.92","lowerLimit":"13.99","upperLimit":"20.47"}]}]},{"title":"Day 36: Flavivirus-negative Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"80"},{"groupId":"OG003","value":"92"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.00","lowerLimit":"NA","upperLimit":"NA","comment":"Due to not enough variability in the values, the CI (upper and lower limit) could not be calculated."},{"groupId":"OG001","value":"1428.20","lowerLimit":"1110.81","upperLimit":"1836.29"},{"groupId":"OG002","value":"1237.86","lowerLimit":"923.46","upperLimit":"1659.31"},{"groupId":"OG003","value":"23.16","lowerLimit":"17.78","upperLimit":"30.17"}]}]},{"title":"Day 57: Flavivirus-negative Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.00","lowerLimit":"NA","upperLimit":"NA","comment":"Due to not enough variability in the values, the CI (upper and lower limit) could not be calculated."},{"groupId":"OG001","value":"2291.24","lowerLimit":"1821.46","upperLimit":"2882.20"},{"groupId":"OG002","value":"2235.55","lowerLimit":"1826.02","upperLimit":"2736.92"},{"groupId":"OG003","value":"280.91","lowerLimit":"211.58","upperLimit":"372.97"}]}]},{"title":"Day 1: Flavivirus-positive Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"61.39","lowerLimit":"41.21","upperLimit":"91.45"},{"groupId":"OG001","value":"61.63","lowerLimit":"42.84","upperLimit":"88.66"},{"groupId":"OG002","value":"47.15","lowerLimit":"31.65","upperLimit":"70.26"},{"groupId":"OG003","value":"62.55","lowerLimit":"41.06","upperLimit":"95.28"}]}]},{"title":"Day 8: Flavivirus-positive Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"51.65","lowerLimit":"35.80","upperLimit":"74.50"},{"groupId":"OG001","value":"275.14","lowerLimit":"159.62","upperLimit":"474.24"},{"groupId":"OG002","value":"348.73","lowerLimit":"193.37","upperLimit":"628.91"},{"groupId":"OG003","value":"47.58","lowerLimit":"32.70","upperLimit":"69.24"}]}]},{"title":"Day 29: Flavivirus-positive Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"67.27","lowerLimit":"45.25","upperLimit":"99.98"},{"groupId":"OG001","value":"1040.81","lowerLimit":"680.49","upperLimit":"1591.92"},{"groupId":"OG002","value":"1067.67","lowerLimit":"711.80","upperLimit":"1601.47"},{"groupId":"OG003","value":"61.27","lowerLimit":"40.18","upperLimit":"93.42"}]}]},{"title":"Day 36: Flavivirus-positive Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"51.54","lowerLimit":"35.96","upperLimit":"73.87"},{"groupId":"OG001","value":"1260.49","lowerLimit":"898.36","upperLimit":"1768.61"},{"groupId":"OG002","value":"1504.49","lowerLimit":"1076.56","upperLimit":"2102.53"},{"groupId":"OG003","value":"493.88","lowerLimit":"273.73","upperLimit":"891.11"}]}]},{"title":"Day 57: Flavivirus-positive Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"65.50","lowerLimit":"43.82","upperLimit":"97.91"},{"groupId":"OG001","value":"2246.56","lowerLimit":"1727.41","upperLimit":"2921.74"},{"groupId":"OG002","value":"2253.47","lowerLimit":"1681.38","upperLimit":"3020.20"},{"groupId":"OG003","value":"2002.83","lowerLimit":"1367.92","upperLimit":"2932.43"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Fold Rise (GMFR) of ZIKV-Specific nAbs at Days 8, 29, 36, and 57, as Measured by PRNT50 and PRNT80","description":"Antibody values reported as below the LLOQ were replaced by 0.5 \\* LLOQ. Values that were greater than the ULOQ were converted to the ULOQ. LLOQ=91; ULOQ=248. 95% CI was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation.","populationDescription":"The PPAMI included all participants who received any study injection, who did not have major protocol deviations that impacted AMI response, and who complied with the injection schedule and the timing of immunogenicity blood sampling to have post-injection results available for at least 1 assay component of AMI at the corresponding visit. Here, 'Number analyzed' = participants evaluable for specified categories.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"ratio","timeFrame":"Days 8, 29, 36, and 57","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to mRNA-1893 administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG001","title":"mRNA-1893 Low Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG002","title":"mRNA-1893 High Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG003","title":"mRNA-1893 High Dose (1-Dose Regimen)","description":"Participants received placebo matched to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There was 28-day interval between vaccinations."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"classes":[{"title":"Day 8: All Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"161"},{"groupId":"OG003","value":"162"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.02","lowerLimit":"0.94","upperLimit":"1.11"},{"groupId":"OG001","value":"1.91","lowerLimit":"1.55","upperLimit":"2.36"},{"groupId":"OG002","value":"1.94","lowerLimit":"1.54","upperLimit":"2.43"},{"groupId":"OG003","value":"0.98","lowerLimit":"0.87","upperLimit":"1.1"}]}]},{"title":"Day 29: All Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"162"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.10","lowerLimit":"0.99","upperLimit":"1.22"},{"groupId":"OG001","value":"2.47","lowerLimit":"1.98","upperLimit":"3.08"},{"groupId":"OG002","value":"2.57","lowerLimit":"2.05","upperLimit":"3.23"},{"groupId":"OG003","value":"1.00","lowerLimit":"0.93","upperLimit":"1.08"}]}]},{"title":"Day 36: All Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"161"},{"groupId":"OG003","value":"162"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","lowerLimit":"0.89","upperLimit":"1.04"},{"groupId":"OG001","value":"8.06","lowerLimit":"6.30","upperLimit":"10.32"},{"groupId":"OG002","value":"7.55","lowerLimit":"5.91","upperLimit":"9.63"},{"groupId":"OG003","value":"1.98","lowerLimit":"1.59","upperLimit":"2.48"}]}]},{"title":"Day 57: All Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.01","lowerLimit":"0.93","upperLimit":"1.09"},{"groupId":"OG001","value":"6.98","lowerLimit":"5.68","upperLimit":"8.59"},{"groupId":"OG002","value":"7.97","lowerLimit":"6.45","upperLimit":"9.85"},{"groupId":"OG003","value":"2.75","lowerLimit":"2.18","upperLimit":"3.46"}]}]},{"title":"Day 8: Flavivirus-negative Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"Due to not enough variability in the values, the CI (upper and lower limit) could not be calculated."},{"groupId":"OG001","value":"0.99","lowerLimit":"0.95","upperLimit":"1.03"},{"groupId":"OG002","value":"1.06","lowerLimit":"0.97","upperLimit":"1.15"},{"groupId":"OG003","value":"1.04","lowerLimit":"0.95","upperLimit":"1.13"}]}]},{"title":"Day 29: Flavivirus-negative Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.02","lowerLimit":"0.98","upperLimit":"1.06"},{"groupId":"OG001","value":"1.14","lowerLimit":"1.02","upperLimit":"1.27"},{"groupId":"OG002","value":"1.48","lowerLimit":"1.24","upperLimit":"1.77"},{"groupId":"OG003","value":"1.01","lowerLimit":"0.98","upperLimit":"1.03"}]}]},{"title":"Day 36: Flavivirus-negative Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"80"},{"groupId":"OG003","value":"92"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"Due to not enough variability in the values, the CI (upper and lower limit) could not be calculated."},{"groupId":"OG001","value":"9.43","lowerLimit":"6.70","upperLimit":"13.26"},{"groupId":"OG002","value":"7.56","lowerLimit":"5.48","upperLimit":"10.42"},{"groupId":"OG003","value":"1.16","lowerLimit":"1.00","upperLimit":"1.34"}]}]},{"title":"Day 57: Flavivirus-negative Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"Due to not enough variability in the values, the CI (upper and lower limit) could not be calculated."},{"groupId":"OG001","value":"6.46","lowerLimit":"4.92","upperLimit":"8.48"},{"groupId":"OG002","value":"7.98","lowerLimit":"6.11","upperLimit":"10.43"},{"groupId":"OG003","value":"1.42","lowerLimit":"1.20","upperLimit":"1.68"}]}]},{"title":"Day 8: Flavivirus-positive Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"78"},{"groupId":"OG003","value":"66"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.04","lowerLimit":"0.90","upperLimit":"1.21"},{"groupId":"OG001","value":"3.39","lowerLimit":"2.37","upperLimit":"4.84"},{"groupId":"OG002","value":"3.70","lowerLimit":"2.44","upperLimit":"5.61"},{"groupId":"OG003","value":"0.90","lowerLimit":"0.69","upperLimit":"1.19"}]}]},{"title":"Day 29: Flavivirus-positive Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.18","lowerLimit":"0.96","upperLimit":"1.43"},{"groupId":"OG001","value":"4.84","lowerLimit":"3.42","upperLimit":"6.85"},{"groupId":"OG002","value":"4.48","lowerLimit":"3.03","upperLimit":"6.61"},{"groupId":"OG003","value":"1.00","lowerLimit":"0.83","upperLimit":"1.20"}]}]},{"title":"Day 36: Flavivirus-positive Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.93","lowerLimit":"0.81","upperLimit":"1.08"},{"groupId":"OG001","value":"7.00","lowerLimit":"4.85","upperLimit":"10.09"},{"groupId":"OG002","value":"7.38","lowerLimit":"5.04","upperLimit":"10.81"},{"groupId":"OG003","value":"4.27","lowerLimit":"2.74","upperLimit":"6.64"}]}]},{"title":"Day 57: Flavivirus-positive Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.01","lowerLimit":"0.87","upperLimit":"1.19"},{"groupId":"OG001","value":"7.44","lowerLimit":"5.40","upperLimit":"10.25"},{"groupId":"OG002","value":"7.60","lowerLimit":"5.42","upperLimit":"10.66"},{"groupId":"OG003","value":"7.03","lowerLimit":"4.61","upperLimit":"10.70"}]}]},{"title":"Day 8: All Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"161"},{"groupId":"OG003","value":"162"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","lowerLimit":"0.94","upperLimit":"1.01"},{"groupId":"OG001","value":"1.93","lowerLimit":"1.57","upperLimit":"2.36"},{"groupId":"OG002","value":"1.98","lowerLimit":"1.57","upperLimit":"2.49"},{"groupId":"OG003","value":"1.03","lowerLimit":"0.98","upperLimit":"1.09"}]}]},{"title":"Day 29: All Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"162"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"0.96","upperLimit":"1.04"},{"groupId":"OG001","value":"2.35","lowerLimit":"1.88","upperLimit":"2.94"},{"groupId":"OG002","value":"2.29","lowerLimit":"1.82","upperLimit":"2.90"},{"groupId":"OG003","value":"1.01","lowerLimit":"0.99","upperLimit":"1.03"}]}]},{"title":"Day 36: All Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"161"},{"groupId":"OG003","value":"162"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","lowerLimit":"0.92","upperLimit":"1.01"},{"groupId":"OG001","value":"5.85","lowerLimit":"4.72","upperLimit":"7.27"},{"groupId":"OG002","value":"6.40","lowerLimit":"5.06","upperLimit":"8.09"},{"groupId":"OG003","value":"2.02","lowerLimit":"1.63","upperLimit":"2.52"}]}]},{"title":"Day 57: All Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","lowerLimit":"0.94","upperLimit":"1.04"},{"groupId":"OG001","value":"5.21","lowerLimit":"4.28","upperLimit":"6.33"},{"groupId":"OG002","value":"5.87","lowerLimit":"4.79","upperLimit":"7.21"},{"groupId":"OG003","value":"2.47","lowerLimit":"1.94","upperLimit":"3.13"}]}]},{"title":"Day 8: Flavivirus-negative Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"Due to not enough variability in the values, the CI (upper and lower limit) could not be calculated."},{"groupId":"OG001","value":"1.02","lowerLimit":"0.99","upperLimit":"1.05"},{"groupId":"OG002","value":"1.04","lowerLimit":"0.96","upperLimit":"1.14"},{"groupId":"OG003","value":"1.00","lowerLimit":"0.98","upperLimit":"1.01"}]}]},{"title":"Day 29: Flavivirus-negative Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.03","lowerLimit":"0.97","upperLimit":"1.08"},{"groupId":"OG001","value":"1.04","lowerLimit":"0.97","upperLimit":"1.11"},{"groupId":"OG002","value":"1.16","lowerLimit":"1.01","upperLimit":"1.32"},{"groupId":"OG003","value":"1.00","lowerLimit":"0.99","upperLimit":"1.01"}]}]},{"title":"Day 36: Flavivirus-negative Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"80"},{"groupId":"OG003","value":"92"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"Due to not enough variability in the values, the CI (upper and lower limit) could not be calculated."},{"groupId":"OG001","value":"5.31","lowerLimit":"4.02","upperLimit":"7.02"},{"groupId":"OG002","value":"5.43","lowerLimit":"4.01","upperLimit":"7.36"},{"groupId":"OG003","value":"1.08","lowerLimit":"0.99","upperLimit":"1.18"}]}]},{"title":"Day 57: Flavivirus-negative Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"Due to not enough variability in the values, the CI (upper and lower limit) could not be calculated."},{"groupId":"OG001","value":"3.86","lowerLimit":"3.03","upperLimit":"4.91"},{"groupId":"OG002","value":"5.30","lowerLimit":"4.24","upperLimit":"6.62"},{"groupId":"OG003","value":"1.13","lowerLimit":"1.04","upperLimit":"1.23"}]}]},{"title":"Day 8: Flavivirus-positive Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"78"},{"groupId":"OG003","value":"66"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.95","lowerLimit":"0.89","upperLimit":"1.01"},{"groupId":"OG001","value":"3.36","lowerLimit":"2.38","upperLimit":"4.74"},{"groupId":"OG002","value":"3.90","lowerLimit":"2.55","upperLimit":"5.94"},{"groupId":"OG003","value":"1.09","lowerLimit":"0.95","upperLimit":"1.24"}]}]},{"title":"Day 29: Flavivirus-positive Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.98","lowerLimit":"0.93","upperLimit":"1.03"},{"groupId":"OG001","value":"4.76","lowerLimit":"3.34","upperLimit":"6.79"},{"groupId":"OG002","value":"4.57","lowerLimit":"3.05","upperLimit":"6.84"},{"groupId":"OG003","value":"1.01","lowerLimit":"0.96","upperLimit":"1.07"}]}]},{"title":"Day 36: Flavivirus-positive Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.94","lowerLimit":"0.86","upperLimit":"1.03"},{"groupId":"OG001","value":"6.36","lowerLimit":"4.55","upperLimit":"8.90"},{"groupId":"OG002","value":"7.40","lowerLimit":"5.12","upperLimit":"10.69"},{"groupId":"OG003","value":"4.95","lowerLimit":"3.21","upperLimit":"7.65"}]}]},{"title":"Day 57: Flavivirus-positive Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.98","lowerLimit":"0.89","upperLimit":"1.07"},{"groupId":"OG001","value":"6.77","lowerLimit":"5.01","upperLimit":"9.15"},{"groupId":"OG002","value":"6.38","lowerLimit":"4.48","upperLimit":"9.08"},{"groupId":"OG003","value":"7.61","lowerLimit":"4.84","upperLimit":"11.96"}]}]}]},{"type":"SECONDARY","title":"GMFR of ZIKV-Specific nAbs at Days 8, 29, 36, and 57, as Measured by MN","description":"Antibody values reported as below the LLOQ were replaced by 0.5 \\* LLOQ. Values that were greater than the ULOQ were converted to the ULOQ. LLOQ=28; ULOQ=11589. 95% CI was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation.","populationDescription":"The PPAMI included all participants who received any study injection, who did not have major protocol deviations that impacted AMI response, and who complied with the injection schedule and the timing of immunogenicity blood sampling to have post-injection results available for at least 1 assay component of AMI at the corresponding visit. Here, 'Number analyzed' = participants evaluable for specified categories.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"ratio","timeFrame":"Days 8, 29, 36, and 57","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to mRNA-1893 administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG001","title":"mRNA-1893 Low Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG002","title":"mRNA-1893 High Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG003","title":"mRNA-1893 High Dose (1-Dose Regimen)","description":"Participants received placebo matched to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There was 28-day interval between vaccinations."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"classes":[{"title":"Day 8: All Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.91","lowerLimit":"0.85","upperLimit":"0.97"},{"groupId":"OG001","value":"2.31","lowerLimit":"1.87","upperLimit":"2.85"},{"groupId":"OG002","value":"3.19","lowerLimit":"2.50","upperLimit":"4.06"},{"groupId":"OG003","value":"0.88","lowerLimit":"0.82","upperLimit":"0.95"}]}]},{"title":"Day 29: All Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"162"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.05","lowerLimit":"0.97","upperLimit":"1.13"},{"groupId":"OG001","value":"14.75","lowerLimit":"12.03","upperLimit":"18.09"},{"groupId":"OG002","value":"21.51","lowerLimit":"17.65","upperLimit":"26.21"},{"groupId":"OG003","value":"1.02","lowerLimit":"0.96","upperLimit":"1.09"}]}]},{"title":"Day 36: All Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"161"},{"groupId":"OG003","value":"162"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.90","lowerLimit":"0.84","upperLimit":"0.97"},{"groupId":"OG001","value":"39.99","lowerLimit":"31.83","upperLimit":"50.25"},{"groupId":"OG002","value":"54.33","lowerLimit":"43.90","upperLimit":"67.23"},{"groupId":"OG003","value":"2.91","lowerLimit":"2.34","upperLimit":"3.64"}]}]},{"title":"Day 57: All Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.03","lowerLimit":"0.96","upperLimit":"1.12"},{"groupId":"OG001","value":"68.55","lowerLimit":"54.98","upperLimit":"85.48"},{"groupId":"OG002","value":"89.69","lowerLimit":"72.82","upperLimit":"110.47"},{"groupId":"OG003","value":"23.01","lowerLimit":"18.89","upperLimit":"28.03"}]}]},{"title":"Day 8: Flavivirus-negative Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"Due to not enough variability in the values, the CI (upper and lower limit) could not be calculated."},{"groupId":"OG001","value":"1.09","lowerLimit":"0.95","upperLimit":"1.25"},{"groupId":"OG002","value":"1.44","lowerLimit":"1.17","upperLimit":"1.79"},{"groupId":"OG003","value":"0.98","lowerLimit":"0.94","upperLimit":"1.02"}]}]},{"title":"Day 29: Flavivirus-negative Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"Due to not enough variability in the values, the CI (upper and lower limit) could not be calculated."},{"groupId":"OG001","value":"12.29","lowerLimit":"9.46","upperLimit":"15.97"},{"groupId":"OG002","value":"20.42","lowerLimit":"15.13","upperLimit":"27.58"},{"groupId":"OG003","value":"1.06","lowerLimit":"0.96","upperLimit":"1.16"}]}]},{"title":"Day 36: Flavivirus-negative Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"80"},{"groupId":"OG003","value":"92"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"Due to not enough variability in the values, the CI (upper and lower limit) could not be calculated."},{"groupId":"OG001","value":"87.88","lowerLimit":"67.32","upperLimit":"114.73"},{"groupId":"OG002","value":"88.42","lowerLimit":"65.96","upperLimit":"118.52"},{"groupId":"OG003","value":"1.45","lowerLimit":"1.22","upperLimit":"1.72"}]}]},{"title":"Day 57: Flavivirus-negative Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"Due to not enough variability in the values, the CI (upper and lower limit) could not be calculated."},{"groupId":"OG001","value":"140.99","lowerLimit":"108.71","upperLimit":"182.85"},{"groupId":"OG002","value":"159.68","lowerLimit":"130.43","upperLimit":"195.49"},{"groupId":"OG003","value":"17.57","lowerLimit":"13.53","upperLimit":"22.80"}]}]},{"title":"Day 8: Flavivirus-positive Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.84","lowerLimit":"0.75","upperLimit":"0.95"},{"groupId":"OG001","value":"4.46","lowerLimit":"3.24","upperLimit":"6.15"},{"groupId":"OG002","value":"7.40","lowerLimit":"5.12","upperLimit":"10.68"},{"groupId":"OG003","value":"0.76","lowerLimit":"0.65","upperLimit":"0.90"}]}]},{"title":"Day 29: Flavivirus-positive Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.10","lowerLimit":"0.94","upperLimit":"1.27"},{"groupId":"OG001","value":"16.89","lowerLimit":"12.39","upperLimit":"23.02"},{"groupId":"OG002","value":"22.64","lowerLimit":"17.39","upperLimit":"29.48"},{"groupId":"OG003","value":"0.98","lowerLimit":"0.89","upperLimit":"1.07"}]}]},{"title":"Day 36: Flavivirus-positive Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","lowerLimit":"0.73","upperLimit":"0.94"},{"groupId":"OG001","value":"20.45","lowerLimit":"15.07","upperLimit":"27.76"},{"groupId":"OG002","value":"31.91","lowerLimit":"24.26","upperLimit":"41.95"},{"groupId":"OG003","value":"7.90","lowerLimit":"5.45","upperLimit":"11.43"}]}]},{"title":"Day 57: Flavivirus-positive Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.07","lowerLimit":"0.92","upperLimit":"1.24"},{"groupId":"OG001","value":"36.45","lowerLimit":"27.11","upperLimit":"49.02"},{"groupId":"OG002","value":"47.79","lowerLimit":"34.69","upperLimit":"65.84"},{"groupId":"OG003","value":"32.02","lowerLimit":"23.77","upperLimit":"43.13"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Seroconversion at Days 8, 29, and 36, as Measured by PRNT50 and PRNT80","description":"Seroconversion was defined as an increase in ZIKV-specific nAb titer from below the LLOQ to a titer equal to or above LLOQ, or an increase of at least 4-fold in ZIKV-specific nAb titer in participants with pre-existing nAb titers. LLOQ=91; ULOQ=24814.","populationDescription":"The PPAMI included all participants who received any study injection, who did not have major protocol deviations that impacted AMI response, and who complied with the injection schedule and the timing of immunogenicity blood sampling to have post-injection results available for at least 1 assay component of AMI at the corresponding visit. Here, 'Number analyzed' = participants evaluable for specified categories.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Days 8, 29, and 36","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to mRNA-1893 administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG001","title":"mRNA-1893 Low Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG002","title":"mRNA-1893 High Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG003","title":"mRNA-1893 High Dose (1-Dose Regimen)","description":"Participants received placebo matched to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There was 28-day interval between vaccinations."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"classes":[{"title":"Day 8: All Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"161"},{"groupId":"OG003","value":"162"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","lowerLimit":"1.01","upperLimit":"7.06"},{"groupId":"OG001","value":"20.9","lowerLimit":"14.90","upperLimit":"27.91"},{"groupId":"OG002","value":"21.1","lowerLimit":"15.09","upperLimit":"28.24"},{"groupId":"OG003","value":"4.3","lowerLimit":"1.75","upperLimit":"8.70"}]}]},{"title":"Day 29: All Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"162"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","lowerLimit":"3.42","upperLimit":"11.75"},{"groupId":"OG001","value":"33.3","lowerLimit":"26.13","upperLimit":"41.16"},{"groupId":"OG002","value":"38.3","lowerLimit":"30.76","upperLimit":"46.22"},{"groupId":"OG003","value":"3.7","lowerLimit":"1.36","upperLimit":"7.84"}]}]},{"title":"Day 36: All Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"161"},{"groupId":"OG003","value":"162"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","lowerLimit":"0.38","upperLimit":"5.32"},{"groupId":"OG001","value":"76.1","lowerLimit":"68.78","upperLimit":"82.40"},{"groupId":"OG002","value":"75.2","lowerLimit":"67.74","upperLimit":"81.62"},{"groupId":"OG003","value":"21.0","lowerLimit":"14.99","upperLimit":"28.07"}]}]},{"title":"Day 8: Flavivirus-negative Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.00","upperLimit":"4.80"},{"groupId":"OG001","value":"0","lowerLimit":"0.00","upperLimit":"4.99"},{"groupId":"OG002","value":"2.5","lowerLimit":"0.30","upperLimit":"8.64"},{"groupId":"OG003","value":"1.1","lowerLimit":"0.03","upperLimit":"5.85"}]}]},{"title":"Day 29: Flavivirus-negative Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.03","upperLimit":"7.11"},{"groupId":"OG001","value":"8.5","lowerLimit":"3.16","upperLimit":"17.49"},{"groupId":"OG002","value":"25.9","lowerLimit":"16.82","upperLimit":"36.86"},{"groupId":"OG003","value":"1.1","lowerLimit":"0.03","upperLimit":"5.85"}]}]},{"title":"Day 36: Flavivirus-negative Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"80"},{"groupId":"OG003","value":"92"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.00","upperLimit":"4.74"},{"groupId":"OG001","value":"86.1","lowerLimit":"75.94","upperLimit":"93.13"},{"groupId":"OG002","value":"78.8","lowerLimit":"68.17","upperLimit":"87.11"},{"groupId":"OG003","value":"4.3","lowerLimit":"1.20","upperLimit":"10.76"}]}]},{"title":"Day 8: Flavivirus-positive Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"78"},{"groupId":"OG003","value":"66"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","lowerLimit":"1.91","upperLimit":"13.05"},{"groupId":"OG001","value":"39.1","lowerLimit":"28.79","upperLimit":"50.13"},{"groupId":"OG002","value":"41.0","lowerLimit":"30.01","upperLimit":"52.75"},{"groupId":"OG003","value":"9.1","lowerLimit":"3.41","upperLimit":"18.74"}]}]},{"title":"Day 29: Flavivirus-positive Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","lowerLimit":"5.72","upperLimit":"20.35"},{"groupId":"OG001","value":"55.2","lowerLimit":"44.13","upperLimit":"65.85"},{"groupId":"OG002","value":"50.6","lowerLimit":"39.14","upperLimit":"62.08"},{"groupId":"OG003","value":"7.5","lowerLimit":"2.47","upperLimit":"16.56"}]}]},{"title":"Day 36: Flavivirus-positive Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","lowerLimit":"0.73","upperLimit":"9.97"},{"groupId":"OG001","value":"66.7","lowerLimit":"55.75","upperLimit":"76.42"},{"groupId":"OG002","value":"70.9","lowerLimit":"59.58","upperLimit":"80.57"},{"groupId":"OG003","value":"44.8","lowerLimit":"32.60","upperLimit":"57.42"}]}]},{"title":"Day 8: All Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"161"},{"groupId":"OG003","value":"162"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.00","upperLimit":"2.25"},{"groupId":"OG001","value":"19.6","lowerLimit":"13.83","upperLimit":"26.57"},{"groupId":"OG002","value":"19.3","lowerLimit":"13.47","upperLimit":"26.20"},{"groupId":"OG003","value":"1.2","lowerLimit":"0.15","upperLimit":"4.39"}]}]},{"title":"Day 29: All Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"162"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"0.15","upperLimit":"4.36"},{"groupId":"OG001","value":"31.5","lowerLimit":"24.42","upperLimit":"39.23"},{"groupId":"OG002","value":"29.0","lowerLimit":"22.16","upperLimit":"36.65"},{"groupId":"OG003","value":"0","lowerLimit":"0.00","upperLimit":"2.24"}]}]},{"title":"Day 36: All Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"161"},{"groupId":"OG003","value":"162"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"0.15","upperLimit":"4.39"},{"groupId":"OG001","value":"72.4","lowerLimit":"64.86","upperLimit":"79.10"},{"groupId":"OG002","value":"72.0","lowerLimit":"64.44","upperLimit":"78.83"},{"groupId":"OG003","value":"22.8","lowerLimit":"16.62","upperLimit":"30.08"}]}]},{"title":"Day 8: Flavivirus-negative Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.00","upperLimit":"4.80"},{"groupId":"OG001","value":"0","lowerLimit":"0.00","upperLimit":"4.99"},{"groupId":"OG002","value":"1.2","lowerLimit":"0.03","upperLimit":"6.69"},{"groupId":"OG003","value":"0","lowerLimit":"0.00","upperLimit":"3.89"}]}]},{"title":"Day 29: Flavivirus-negative Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.03","upperLimit":"7.11"},{"groupId":"OG001","value":"2.8","lowerLimit":"0.34","upperLimit":"9.81"},{"groupId":"OG002","value":"7.4","lowerLimit":"2.77","upperLimit":"15.43"},{"groupId":"OG003","value":"0","lowerLimit":"0.00","upperLimit":"3.89"}]}]},{"title":"Day 36: Flavivirus-negative Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"80"},{"groupId":"OG003","value":"92"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.00","upperLimit":"4.74"},{"groupId":"OG001","value":"75.0","lowerLimit":"63.40","upperLimit":"84.46"},{"groupId":"OG002","value":"71.3","lowerLimit":"60.05","upperLimit":"80.82"},{"groupId":"OG003","value":"3.3","lowerLimit":"0.68","upperLimit":"9.23"}]}]},{"title":"Day 8: Flavivirus-positive Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"78"},{"groupId":"OG003","value":"66"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.00","upperLimit":"4.20"},{"groupId":"OG001","value":"36.8","lowerLimit":"26.69","upperLimit":"47.80"},{"groupId":"OG002","value":"38.5","lowerLimit":"27.66","upperLimit":"50.17"},{"groupId":"OG003","value":"3.0","lowerLimit":"0.37","upperLimit":"10.52"}]}]},{"title":"Day 29: Flavivirus-positive Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"0.03","upperLimit":"6.31"},{"groupId":"OG001","value":"56.3","lowerLimit":"45.26","upperLimit":"66.94"},{"groupId":"OG002","value":"50.6","lowerLimit":"39.14","upperLimit":"62.08"},{"groupId":"OG003","value":"0","lowerLimit":"0.00","upperLimit":"5.36"}]}]},{"title":"Day 36: Flavivirus-positive Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","lowerLimit":"0.29","upperLimit":"8.24"},{"groupId":"OG001","value":"69.0","lowerLimit":"58.14","upperLimit":"78.45"},{"groupId":"OG002","value":"72.2","lowerLimit":"60.93","upperLimit":"81.65"},{"groupId":"OG003","value":"50.7","lowerLimit":"38.24","upperLimit":"63.18"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Seroconversion at Days 8, 29, 36, and 57, as Measured by MN","description":"Seroconversion was defined as an increase in ZIKV-specific nAb titer from below the LLOQ to a titer equal to or above LLOQ, or an increase of at least 4-fold in ZIKV-specific nAb titer in participants with pre-existing nAb titers. LLOQ=28; ULOQ=11589.","populationDescription":"The PPAMI included all participants who received any study injection, who did not have major protocol deviations that impacted AMI response, and who complied with the injection schedule and the timing of immunogenicity blood sampling to have post-injection results available for at least 1 assay component of AMI at the corresponding visit. Here, 'Number analyzed' = participants evaluable for specified categories.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Days 8, 29, 36, and 57","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to mRNA-1893 administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG001","title":"mRNA-1893 Low Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG002","title":"mRNA-1893 High Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG003","title":"mRNA-1893 High Dose (1-Dose Regimen)","description":"Participants received placebo matched to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There was 28-day interval between vaccinations."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"classes":[{"title":"Day 8: All Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"0.15","upperLimit":"4.39"},{"groupId":"OG001","value":"35.0","lowerLimit":"27.68","upperLimit":"42.82"},{"groupId":"OG002","value":"41.4","lowerLimit":"33.69","upperLimit":"49.35"},{"groupId":"OG003","value":"1.2","lowerLimit":"0.15","upperLimit":"4.36"}]}]},{"title":"Day 29: All Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"162"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","lowerLimit":"0.38","upperLimit":"5.28"},{"groupId":"OG001","value":"93.2","lowerLimit":"88.18","upperLimit":"96.56"},{"groupId":"OG002","value":"95.7","lowerLimit":"91.30","upperLimit":"98.25"},{"groupId":"OG003","value":"1.8","lowerLimit":"0.38","upperLimit":"5.28"}]}]},{"title":"Day 36: All Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"161"},{"groupId":"OG003","value":"162"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"0.15","upperLimit":"4.39"},{"groupId":"OG001","value":"92.6","lowerLimit":"87.49","upperLimit":"96.14"},{"groupId":"OG002","value":"96.3","lowerLimit":"92.07","upperLimit":"98.62"},{"groupId":"OG003","value":"40.7","lowerLimit":"33.10","upperLimit":"48.73"}]}]},{"title":"Day 57: All Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"},{"groupId":"OG003","value":"163"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","lowerLimit":"0.38","upperLimit":"5.28"},{"groupId":"OG001","value":"95.7","lowerLimit":"91.35","upperLimit":"98.26"},{"groupId":"OG002","value":"97.5","lowerLimit":"93.80","upperLimit":"99.32"},{"groupId":"OG003","value":"95.7","lowerLimit":"91.35","upperLimit":"98.26"}]}]},{"title":"Day 8: Flavivirus-negative Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.00","upperLimit":"4.80"},{"groupId":"OG001","value":"8.3","lowerLimit":"3.12","upperLimit":"17.26"},{"groupId":"OG002","value":"16.0","lowerLimit":"8.83","upperLimit":"25.88"},{"groupId":"OG003","value":"0","lowerLimit":"0.00","upperLimit":"3.89"}]}]},{"title":"Day 29: Flavivirus-negative Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.00","upperLimit":"4.74"},{"groupId":"OG001","value":"97.2","lowerLimit":"90.19","upperLimit":"99.66"},{"groupId":"OG002","value":"95.1","lowerLimit":"87.84","upperLimit":"98.64"},{"groupId":"OG003","value":"1.1","lowerLimit":"0.03","upperLimit":"5.85"}]}]},{"title":"Day 36: Flavivirus-negative Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"80"},{"groupId":"OG003","value":"92"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.00","upperLimit":"4.74"},{"groupId":"OG001","value":"98.6","lowerLimit":"92.50","upperLimit":"99.96"},{"groupId":"OG002","value":"97.5","lowerLimit":"91.26","upperLimit":"99.70"},{"groupId":"OG003","value":"18.5","lowerLimit":"11.15","upperLimit":"27.93"}]}]},{"title":"Day 57: Flavivirus-negative Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.00","upperLimit":"4.74"},{"groupId":"OG001","value":"98.6","lowerLimit":"92.50","upperLimit":"99.96"},{"groupId":"OG002","value":"100.0","lowerLimit":"95.55","upperLimit":"100.0"},{"groupId":"OG003","value":"94.6","lowerLimit":"87.90","upperLimit":"98.23"}]}]},{"title":"Day 8: Flavivirus-positive Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","lowerLimit":"0.28","upperLimit":"8.15"},{"groupId":"OG001","value":"58.6","lowerLimit":"47.55","upperLimit":"69.08"},{"groupId":"OG002","value":"68.4","lowerLimit":"56.92","upperLimit":"78.37"},{"groupId":"OG003","value":"3.0","lowerLimit":"0.36","upperLimit":"10.37"}]}]},{"title":"Day 29: Flavivirus-positive Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","lowerLimit":"0.73","upperLimit":"9.86"},{"groupId":"OG001","value":"89.7","lowerLimit":"81.27","upperLimit":"95.16"},{"groupId":"OG002","value":"96.2","lowerLimit":"89.30","upperLimit":"99.21"},{"groupId":"OG003","value":"3.0","lowerLimit":"0.36","upperLimit":"10.37"}]}]},{"title":"Day 36: Flavivirus-positive Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","lowerLimit":"0.29","upperLimit":"8.24"},{"groupId":"OG001","value":"87.4","lowerLimit":"78.50","upperLimit":"93.52"},{"groupId":"OG002","value":"94.9","lowerLimit":"87.54","upperLimit":"98.60"},{"groupId":"OG003","value":"71.6","lowerLimit":"59.31","upperLimit":"81.99"}]}]},{"title":"Day 57: Flavivirus-positive Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","lowerLimit":"0.73","upperLimit":"9.86"},{"groupId":"OG001","value":"93.1","lowerLimit":"85.59","upperLimit":"97.43"},{"groupId":"OG002","value":"94.9","lowerLimit":"87.54","upperLimit":"98.60"},{"groupId":"OG003","value":"97.0","lowerLimit":"89.63","upperLimit":"99.64"}]}]}]},{"type":"SECONDARY","title":"Percentage of Initially Seronegative Participants With a Seroresponse at Days 8, 29, and 36, as Measured by PRNT50 and PRNT80","description":"Seroresponse was defined as an increase in ZIKV-specific nAb titer from below the LLOQ to greater than or equal to the LLOQ. LLOQ=91; ULOQ=24814.","populationDescription":"The PPAMI included all participants who received any study injection, who did not have major protocol deviations that impacted AMI response, and who complied with the injection schedule and timing of immunogenicity blood sampling to have post-injection results available for at least 1 assay component of AMI at the corresponding visit. 'Overall number of participants analyzed' = participants evaluable for this outcome measure. 'Number analyzed' = participants evaluable for specified categories.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Days 8, 29, and 36","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to mRNA-1893 administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG001","title":"mRNA-1893 Low Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG002","title":"mRNA-1893 High Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG003","title":"mRNA-1893 High Dose (1-Dose Regimen)","description":"Participants received placebo matched to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There was 28-day interval between vaccinations."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"classes":[{"title":"Day 8: Flavivirus-negative Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.00","upperLimit":"4.80"},{"groupId":"OG001","value":"0","lowerLimit":"0.00","upperLimit":"5.13"},{"groupId":"OG002","value":"2.5","lowerLimit":"0.30","upperLimit":"8.64"},{"groupId":"OG003","value":"1.1","lowerLimit":"0.03","upperLimit":"6.04"}]}]},{"title":"Day 29: Flavivirus-negative Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.03","upperLimit":"7.11"},{"groupId":"OG001","value":"8.7","lowerLimit":"3.26","upperLimit":"17.97"},{"groupId":"OG002","value":"25.9","lowerLimit":"16.82","upperLimit":"36.86"},{"groupId":"OG003","value":"1.1","lowerLimit":"0.03","upperLimit":"6.04"}]}]},{"title":"Day 36: Flavivirus-negative Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"80"},{"groupId":"OG003","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.00","upperLimit":"4.74"},{"groupId":"OG001","value":"88.6","lowerLimit":"78.72","upperLimit":"94.93"},{"groupId":"OG002","value":"78.8","lowerLimit":"68.17","upperLimit":"87.11"},{"groupId":"OG003","value":"2.2","lowerLimit":"0.27","upperLimit":"7.88"}]}]},{"title":"Day 8: Flavivirus-negative Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.00","upperLimit":"4.80"},{"groupId":"OG001","value":"0","lowerLimit":"0.00","upperLimit":"5.13"},{"groupId":"OG002","value":"1.2","lowerLimit":"0.03","upperLimit":"6.69"},{"groupId":"OG003","value":"0","lowerLimit":"0.00","upperLimit":"4.02"}]}]},{"title":"Day 29: Flavivirus-negative Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.03","upperLimit":"7.11"},{"groupId":"OG001","value":"2.9","lowerLimit":"0.35","upperLimit":"10.08"},{"groupId":"OG002","value":"7.4","lowerLimit":"2.77","upperLimit":"15.43"},{"groupId":"OG003","value":"0","lowerLimit":"0.00","upperLimit":"4.02"}]}]},{"title":"Day 36: Flavivirus-negative Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"80"},{"groupId":"OG003","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.00","upperLimit":"4.74"},{"groupId":"OG001","value":"77.1","lowerLimit":"65.55","upperLimit":"86.33"},{"groupId":"OG002","value":"71.3","lowerLimit":"60.05","upperLimit":"80.82"},{"groupId":"OG003","value":"0","lowerLimit":"0.00","upperLimit":"4.06"}]}]}]},{"type":"SECONDARY","title":"Percentage of Initially Seronegative Participants With a Seroresponse at Days 8, 29, 36, and 57, as Measured by MN","description":"Seroresponse was defined as an increase in ZIKV-specific nAb titer from below the LLOQ to greater than or equal to the LLOQ. LLOQ=28; ULOQ=11589.","populationDescription":"The PPAMI included all participants who received any study injection, who did not have major protocol deviations that impacted AMI response, and who complied with the injection schedule and timing of immunogenicity blood sampling to have post-injection results available for at least 1 assay component of AMI at the corresponding visit. 'Overall number of participants analyzed' = participants evaluable for this outcome measure. 'Number analyzed' = participants evaluable for specified categories.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Days 8, 29, 36, and 57","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to mRNA-1893 administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG001","title":"mRNA-1893 Low Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG002","title":"mRNA-1893 High Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG003","title":"mRNA-1893 High Dose (1-Dose Regimen)","description":"Participants received placebo matched to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There was 28-day interval between vaccinations."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"90"}]}],"classes":[{"title":"Day 8: Flavivirus-negative Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.00","upperLimit":"4.80"},{"groupId":"OG001","value":"5.8","lowerLimit":"1.60","upperLimit":"14.18"},{"groupId":"OG002","value":"16.0","lowerLimit":"8.83","upperLimit":"25.88"},{"groupId":"OG003","value":"0","lowerLimit":"0.00","upperLimit":"4.02"}]}]},{"title":"Day 29: Flavivirus-negative Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.00","upperLimit":"4.74"},{"groupId":"OG001","value":"97.1","lowerLimit":"89.78","upperLimit":"99.64"},{"groupId":"OG002","value":"95.1","lowerLimit":"87.84","upperLimit":"98.64"},{"groupId":"OG003","value":"1.1","lowerLimit":"0.03","upperLimit":"6.04"}]}]},{"title":"Day 36: Flavivirus-negative Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"80"},{"groupId":"OG003","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.00","upperLimit":"4.74"},{"groupId":"OG001","value":"98.6","lowerLimit":"92.19","upperLimit":"99.96"},{"groupId":"OG002","value":"97.5","lowerLimit":"91.26","upperLimit":"99.70"},{"groupId":"OG003","value":"15.7","lowerLimit":"8.88","upperLimit":"24.98"}]}]},{"title":"Day 57: Flavivirus-negative Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.00","upperLimit":"4.74"},{"groupId":"OG001","value":"98.6","lowerLimit":"92.19","upperLimit":"99.96"},{"groupId":"OG002","value":"100.0","lowerLimit":"95.55","upperLimit":"100.0"},{"groupId":"OG003","value":"94.4","lowerLimit":"87.51","upperLimit":"98.17"}]}]}]},{"type":"SECONDARY","title":"Percentage of Initially Seropositive Participants With a 2-Fold Increase in ZIKV-Specific nAb Titers as Compared With Baseline, as Measured by PRNT50 and PRNT80","description":"≥2-fold increase from baseline was defined as a ≥2 \\* LLOQ for participants with baseline undetectable antibody titer, or a 2-times or higher ratio in participants with pre-existing nAb titers. LLOQ=91","populationDescription":"The PPAMI included all participants who received any study injection, who did not have major protocol deviations that impacted AMI response, and who complied with the injection schedule and timing of immunogenicity blood sampling to have post-injection results available for at least 1 assay component of AMI at the corresponding visit. 'Overall number of participants analyzed' = participants evaluable for this outcome measure. 'Number analyzed' = participants evaluable for specified categories.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Days 8, 29, 36, and 57","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to mRNA-1893 administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG001","title":"mRNA-1893 Low Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG002","title":"mRNA-1893 High Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG003","title":"mRNA-1893 High Dose (1-Dose Regimen)","description":"Participants received placebo matched to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There was 28-day interval between vaccinations."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"classes":[{"title":"Day 8: Flavivirus-positive Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"78"},{"groupId":"OG003","value":"66"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","lowerLimit":"3.34","upperLimit":"16.05"},{"groupId":"OG001","value":"41.4","lowerLimit":"30.92","upperLimit":"52.45"},{"groupId":"OG002","value":"38.5","lowerLimit":"27.66","upperLimit":"50.17"},{"groupId":"OG003","value":"6.1","lowerLimit":"1.68","upperLimit":"14.80"}]}]},{"title":"Day 29: Flavivirus-positive Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","lowerLimit":"4.90","upperLimit":"18.94"},{"groupId":"OG001","value":"55.2","lowerLimit":"44.13","upperLimit":"65.85"},{"groupId":"OG002","value":"44.3","lowerLimit":"33.12","upperLimit":"55.92"},{"groupId":"OG003","value":"6.0","lowerLimit":"1.65","upperLimit":"14.59"}]}]},{"title":"Day 36: Flavivirus-positive Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","lowerLimit":"1.30","upperLimit":"11.61"},{"groupId":"OG001","value":"60.9","lowerLimit":"49.87","upperLimit":"71.21"},{"groupId":"OG002","value":"63.3","lowerLimit":"51.69","upperLimit":"73.86"},{"groupId":"OG003","value":"46.3","lowerLimit":"34.00","upperLimit":"58.88"}]}]},{"title":"Day 57: Flavivirus-positive Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","lowerLimit":"1.91","upperLimit":"13.05"},{"groupId":"OG001","value":"63.2","lowerLimit":"52.20","upperLimit":"73.31"},{"groupId":"OG002","value":"63.3","lowerLimit":"51.69","upperLimit":"73.86"},{"groupId":"OG003","value":"62.7","lowerLimit":"50.01","upperLimit":"74.20"}]}]},{"title":"Day 8: Flavivirus-positive Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"78"},{"groupId":"OG003","value":"66"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.00","upperLimit":"4.20"},{"groupId":"OG001","value":"40.2","lowerLimit":"29.85","upperLimit":"51.29"},{"groupId":"OG002","value":"38.5","lowerLimit":"27.66","upperLimit":"50.17"},{"groupId":"OG003","value":"4.5","lowerLimit":"0.95","upperLimit":"12.71"}]}]},{"title":"Day 29: Flavivirus-positive Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.00","upperLimit":"4.20"},{"groupId":"OG001","value":"49.4","lowerLimit":"38.53","upperLimit":"60.36"},{"groupId":"OG002","value":"43.0","lowerLimit":"31.94","upperLimit":"54.67"},{"groupId":"OG003","value":"1.5","lowerLimit":"0.04","upperLimit":"8.04"}]}]},{"title":"Day 36: Flavivirus-positive Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"0.03","upperLimit":"6.38"},{"groupId":"OG001","value":"63.2","lowerLimit":"52.20","upperLimit":"73.31"},{"groupId":"OG002","value":"62.0","lowerLimit":"50.41","upperLimit":"72.72"},{"groupId":"OG003","value":"50.7","lowerLimit":"38.24","upperLimit":"63.18"}]}]},{"title":"Day 57: Flavivirus-positive Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","lowerLimit":"0.73","upperLimit":"9.86"},{"groupId":"OG001","value":"63.2","lowerLimit":"52.20","upperLimit":"73.31"},{"groupId":"OG002","value":"60.8","lowerLimit":"49.13","upperLimit":"71.56"},{"groupId":"OG003","value":"61.2","lowerLimit":"48.50","upperLimit":"72.86"}]}]}]},{"type":"SECONDARY","title":"Percentage of Initially Seropositive Participants With a 4-Fold Increase in ZIKV-Specific nAb Titers as Compared With Baseline, as Measured by PRNT50 and PRNT80","description":"≥4-fold increase from baseline was defined as a ≥4 \\* LLOQ for participants with baseline undetectable antibody titer, or a 4-times or higher ratio in participants with pre-existing nAb titers. LLOQ=91","populationDescription":"The PPAMI included all participants who received any study injection, who did not have major protocol deviations that impacted AMI response, and who complied with the injection schedule and timing of immunogenicity blood sampling to have post-injection results available for at least 1 assay component of AMI at the corresponding visit. 'Overall number of participants analyzed' = participants evaluable for this outcome measure. 'Number analyzed' = participants evaluable for specified categories.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Days 8, 29, 36, and 57","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to mRNA-1893 administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG001","title":"mRNA-1893 Low Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG002","title":"mRNA-1893 High Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG003","title":"mRNA-1893 High Dose (1-Dose Regimen)","description":"Participants received placebo matched to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There was 28-day interval between vaccinations."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"classes":[{"title":"Day 8: Flavivirus-positive Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"78"},{"groupId":"OG003","value":"66"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","lowerLimit":"0.28","upperLimit":"8.15"},{"groupId":"OG001","value":"35.6","lowerLimit":"25.65","upperLimit":"46.62"},{"groupId":"OG002","value":"35.9","lowerLimit":"25.34","upperLimit":"47.56"},{"groupId":"OG003","value":"4.5","lowerLimit":"0.95","upperLimit":"12.71"}]}]},{"title":"Day 29: Flavivirus-positive Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","lowerLimit":"2.60","upperLimit":"14.57"},{"groupId":"OG001","value":"42.5","lowerLimit":"31.99","upperLimit":"53.59"},{"groupId":"OG002","value":"40.5","lowerLimit":"29.60","upperLimit":"52.15"},{"groupId":"OG003","value":"4.5","lowerLimit":"0.93","upperLimit":"12.53"}]}]},{"title":"Day 36: Flavivirus-positive Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"0.03","upperLimit":"6.38"},{"groupId":"OG001","value":"50.6","lowerLimit":"39.64","upperLimit":"61.47"},{"groupId":"OG002","value":"50.6","lowerLimit":"39.14","upperLimit":"62.08"},{"groupId":"OG003","value":"38.8","lowerLimit":"27.14","upperLimit":"51.50"}]}]},{"title":"Day 57: Flavivirus-positive Participants by PRNT50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","lowerLimit":"0.28","upperLimit":"8.15"},{"groupId":"OG001","value":"52.9","lowerLimit":"41.87","upperLimit":"63.67"},{"groupId":"OG002","value":"48.1","lowerLimit":"36.71","upperLimit":"59.64"},{"groupId":"OG003","value":"47.8","lowerLimit":"35.40","upperLimit":"60.33"}]}]},{"title":"Day 8: Flavivirus-positive Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"78"},{"groupId":"OG003","value":"66"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.00","upperLimit":"4.20"},{"groupId":"OG001","value":"35.6","lowerLimit":"25.65","upperLimit":"46.62"},{"groupId":"OG002","value":"33.3","lowerLimit":"23.06","upperLimit":"44.92"},{"groupId":"OG003","value":"1.5","lowerLimit":"0.04","upperLimit":"8.16"}]}]},{"title":"Day 29: Flavivirus-positive Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.00","upperLimit":"4.20"},{"groupId":"OG001","value":"40.2","lowerLimit":"29.85","upperLimit":"51.29"},{"groupId":"OG002","value":"38.0","lowerLimit":"27.28","upperLimit":"49.59"},{"groupId":"OG003","value":"0","lowerLimit":"0.00","upperLimit":"5.36"}]}]},{"title":"Day 36: Flavivirus-positive Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.00","upperLimit":"4.25"},{"groupId":"OG001","value":"50.6","lowerLimit":"39.64","upperLimit":"61.47"},{"groupId":"OG002","value":"50.6","lowerLimit":"39.14","upperLimit":"62.08"},{"groupId":"OG003","value":"43.3","lowerLimit":"31.22","upperLimit":"55.96"}]}]},{"title":"Day 57: Flavivirus-positive Participants by PRNT80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"0.03","upperLimit":"6.31"},{"groupId":"OG001","value":"50.6","lowerLimit":"39.64","upperLimit":"61.47"},{"groupId":"OG002","value":"43.0","lowerLimit":"31.94","upperLimit":"54.67"},{"groupId":"OG003","value":"49.3","lowerLimit":"36.82","upperLimit":"61.76"}]}]}]},{"type":"SECONDARY","title":"Percentage of Initially Seropositive Participants With a 2-Fold Increase in ZIKV-Specific nAb Titers as Compared With Baseline, as Measured by MN","description":"≥2-fold increase from baseline was defined as a ≥2 \\* LLOQ for participants with baseline undetectable antibody titer, or a 2-times or higher ratio in participants with pre-existing nAb titers. LLOQ=28.","populationDescription":"The PPAMI included all participants who received any study injection, who did not have major protocol deviations that impacted AMI response, and who complied with the injection schedule and timing of immunogenicity blood sampling to have post-injection results available for at least 1 assay component of AMI at the corresponding visit. 'Overall number of participants analyzed' = participants evaluable for this outcome measure. 'Number analyzed' = participants evaluable for specified categories.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Days 8, 29, 36, and 57","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to mRNA-1893 administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG001","title":"mRNA-1893 Low Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG002","title":"mRNA-1893 High Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG003","title":"mRNA-1893 High Dose (1-Dose Regimen)","description":"Participants received placebo matched to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There was 28-day interval between vaccinations."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"classes":[{"title":"Day 8: Flavivirus-positive Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","lowerLimit":"0.73","upperLimit":"9.86"},{"groupId":"OG001","value":"58.6","lowerLimit":"47.55","upperLimit":"69.08"},{"groupId":"OG002","value":"63.3","lowerLimit":"51.69","upperLimit":"73.86"},{"groupId":"OG003","value":"4.5","lowerLimit":"0.93","upperLimit":"12.53"}]}]},{"title":"Day 29: Flavivirus-positive Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","lowerLimit":"0.28","upperLimit":"8.15"},{"groupId":"OG001","value":"87.4","lowerLimit":"78.50","upperLimit":"93.52"},{"groupId":"OG002","value":"96.2","lowerLimit":"89.30","upperLimit":"99.21"},{"groupId":"OG003","value":"0","lowerLimit":"0.00","upperLimit":"5.36"}]}]},{"title":"Day 36: Flavivirus-positive Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","lowerLimit":"1.30","upperLimit":"11.61"},{"groupId":"OG001","value":"92.0","lowerLimit":"84.12","upperLimit":"96.70"},{"groupId":"OG002","value":"97.5","lowerLimit":"91.15","upperLimit":"99.69"},{"groupId":"OG003","value":"71.6","lowerLimit":"59.31","upperLimit":"81.99"}]}]},{"title":"Day 57: Flavivirus-positive Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","lowerLimit":"0.28","upperLimit":"8.15"},{"groupId":"OG001","value":"97.7","lowerLimit":"91.94","upperLimit":"99.72"},{"groupId":"OG002","value":"98.7","lowerLimit":"93.15","upperLimit":"99.97"},{"groupId":"OG003","value":"100.0","lowerLimit":"94.64","upperLimit":"100.00"}]}]}]},{"type":"SECONDARY","title":"Percentage of Initially Seropositive Participants With a 4-Fold Increase in ZIKV-Specific nAb Titers as Compared With Baseline, as Measured by MN","description":"≥4-fold increase from baseline was defined as a ≥4 \\* LLOQ for participants with baseline undetectable antibody titer, or a 4-times or higher ratio in participants with pre-existing nAb titers. LLOQ=28.","populationDescription":"The PPAMI included all participants who received any study injection, who did not have major protocol deviations that impacted AMI response, and who complied with the injection schedule and timing of immunogenicity blood sampling to have post-injection results available for at least 1 assay component of AMI at the corresponding visit. 'Overall number of participants analyzed' = participants evaluable for this outcome measure. 'Number analyzed' = participants evaluable for specified categories.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Days 8, 29, 36, and 57","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to mRNA-1893 administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG001","title":"mRNA-1893 Low Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG002","title":"mRNA-1893 High Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG003","title":"mRNA-1893 High Dose (1-Dose Regimen)","description":"Participants received placebo matched to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There was 28-day interval between vaccinations."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"classes":[{"title":"Day 8: Flavivirus-positive Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","lowerLimit":"0.28","upperLimit":"8.15"},{"groupId":"OG001","value":"43.7","lowerLimit":"33.06","upperLimit":"54.74"},{"groupId":"OG002","value":"50.6","lowerLimit":"39.14","upperLimit":"62.08"},{"groupId":"OG003","value":"1.5","lowerLimit":"0.04","upperLimit":"8.04"}]}]},{"title":"Day 29: Flavivirus-positive Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","lowerLimit":"0.28","upperLimit":"8.15"},{"groupId":"OG001","value":"79.3","lowerLimit":"69.29","upperLimit":"87.25"},{"groupId":"OG002","value":"87.3","lowerLimit":"77.95","upperLimit":"93.76"},{"groupId":"OG003","value":"0","lowerLimit":"0.00","upperLimit":"5.36"}]}]},{"title":"Day 36: Flavivirus-positive Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"0.03","upperLimit":"6.38"},{"groupId":"OG001","value":"81.6","lowerLimit":"71.86","upperLimit":"89.11"},{"groupId":"OG002","value":"92.4","lowerLimit":"84.20","upperLimit":"97.16"},{"groupId":"OG003","value":"58.2","lowerLimit":"45.52","upperLimit":"70.15"}]}]},{"title":"Day 57: Flavivirus-positive Participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","lowerLimit":"0.28","upperLimit":"8.15"},{"groupId":"OG001","value":"93.1","lowerLimit":"85.59","upperLimit":"97.43"},{"groupId":"OG002","value":"93.7","lowerLimit":"85.84","upperLimit":"97.91"},{"groupId":"OG003","value":"92.5","lowerLimit":"83.44","upperLimit":"97.53"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Deaths Related to Study Drug","description":"A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, irrespective of its perceived relationship to the study drug. The Investigator assessed the causality by determining whether there was a reasonable possibility that the death was related to the study drug, using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable.","populationDescription":"The Randomized Set included all participants who were randomized in the study, regardless of the participant's treatment status in the study. One participant who was randomized at two sites and received two injections was kept in both arms (Randomized to mRNA-1893 High Dose \\[2-Dose Regimen\\] and mRNA-1893 Low Dose \\[2-Dose Regimen\\]) in Randomized Set for collection and reporting data.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 through Day 196 for Main Study and Day 197 through Day 700 for Extension Period","groups":[{"id":"OG000","title":"Main Study: Placebo","description":"Participants received placebo matched to mRNA-1893 administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG001","title":"Main Study: mRNA-1893 Low Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG002","title":"Main Study: mRNA-1893 High Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29)."},{"id":"OG003","title":"Main Study: mRNA-1893 High Dose (1-Dose Regimen)","description":"Participants received placebo matched to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There was 28-day interval between vaccinations."},{"id":"OG004","title":"Extension Period: Placebo","description":"Participants were followed up for up to Day 700 in the extension period."},{"id":"OG005","title":"Extension Period: mRNA-1893 Low Dose (2-Dose Regimen)","description":"Participants were followed up for up to Day 700 in the extension period."},{"id":"OG006","title":"Extension Period: mRNA-1893 High Dose (2-Dose Regimen)","description":"Participants were followed up for up to Day 700 in the extension period."},{"id":"OG007","title":"Extension Period: mRNA-1893 High Dose (1-Dose Regimen)","description":"Participants were followed up for up to Day 700 in the extension period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"203"},{"groupId":"OG001","value":"202"},{"groupId":"OG002","value":"203"},{"groupId":"OG003","value":"201"},{"groupId":"OG004","value":"113"},{"groupId":"OG005","value":"109"},{"groupId":"OG006","value":"104"},{"groupId":"OG007","value":"116"}]}],"classes":[{"title":"Deaths","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]},{"title":"Deaths Related to Study Drug","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"All-cause mortality and serious adverse events were collected from Day 1 through Day 196 for Main Study and Day 197 through Day 700 for Extension Period. Other (not including serious) unsolicited adverse events were collected up to 28 days after study injection (that is, Day 1 up to Day 57) unless they met the criteria for AESIs, MAAEs or AEs led to discontinuation.","description":"The all-cause mortality was based on the randomized set. The serious and other (not including serious) adverse events were based on the safety set which consisted of all randomized participants who received any study injection. One participant who was randomized at two sites and received two injections was kept in both arms (Randomized to mRNA-1893 High Dose \\[2-Dose Regimen\\] and mRNA-1893 Low Dose \\[2-Dose Regimen\\]) in Randomized Set and Safety Set for collection and reporting data.","eventGroups":[{"id":"EG000","title":"Main Study: Placebo","description":"Participants received placebo matched to mRNA-1893 administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29).","deathsNumAffected":0,"deathsNumAtRisk":203,"seriousNumAffected":5,"seriousNumAtRisk":201,"otherNumAffected":18,"otherNumAtRisk":201},{"id":"EG001","title":"Main Study: mRNA-1893 Low Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29).","deathsNumAffected":0,"deathsNumAtRisk":202,"seriousNumAffected":2,"seriousNumAtRisk":202,"otherNumAffected":20,"otherNumAtRisk":202},{"id":"EG002","title":"Main Study: mRNA-1893 High Dose (2-Dose Regimen)","description":"Participants received mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day interval between vaccinations (administered on Day 1 and Day 29).","deathsNumAffected":0,"deathsNumAtRisk":203,"seriousNumAffected":4,"seriousNumAtRisk":202,"otherNumAffected":24,"otherNumAtRisk":202},{"id":"EG003","title":"Main Study: mRNA-1893 High Dose (1-Dose Regimen)","description":"Participants received placebo matched to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There was 28-day interval between vaccinations.","deathsNumAffected":1,"deathsNumAtRisk":201,"seriousNumAffected":7,"seriousNumAtRisk":198,"otherNumAffected":16,"otherNumAtRisk":198},{"id":"EG004","title":"Extension Period: Placebo","description":"Participants were followed up for up to Day 700 in the extension period.","deathsNumAffected":0,"deathsNumAtRisk":113,"seriousNumAffected":5,"seriousNumAtRisk":113,"otherNumAffected":8,"otherNumAtRisk":113},{"id":"EG005","title":"Extension Period: mRNA-1893 Low Dose (2-Dose Regimen)","description":"Participants were followed up for up to Day 700 in the extension period.","deathsNumAffected":1,"deathsNumAtRisk":109,"seriousNumAffected":4,"seriousNumAtRisk":109,"otherNumAffected":5,"otherNumAtRisk":109},{"id":"EG006","title":"Extension Period: mRNA-1893 High Dose (2-Dose Regimen)","description":"Participants were followed up for up to Day 700 in the extension period.","deathsNumAffected":0,"deathsNumAtRisk":104,"seriousNumAffected":5,"seriousNumAtRisk":104,"otherNumAffected":8,"otherNumAtRisk":104},{"id":"EG007","title":"Extension Period: mRNA-1893 High Dose (1-Dose Regimen)","description":"Participants were followed up for up to Day 700 in the extension period.","deathsNumAffected":0,"deathsNumAtRisk":116,"seriousNumAffected":7,"seriousNumAtRisk":116,"otherNumAffected":10,"otherNumAtRisk":116}],"seriousEvents":[{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":104},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":116}]},{"term":"Diabetic foot infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Large intestine infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":116}]},{"term":"Localised infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Breast cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Meningioma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Uterine leiomyoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Type 2 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Alcohol withdrawal syndrome","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":116}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Factitious disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Major depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Hiatus hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":116}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Intervertebral disc degeneration","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":116}]},{"term":"Lumbar spinal stenosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Rotator cuff tear arthropathy","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Spondylolisthesis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":116}]},{"term":"Renal colic","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Ureterolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Abortion spontaneous","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"BRCA1 gene mutation","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Heart disease congenital","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Trisomy 21","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Alcohol poisoning","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":116}]},{"term":"Burns second degree","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":109},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]},{"term":"Spinal compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":202},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":198},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":104},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":116}]}],"otherEvents":[{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":201},{"groupId":"EG001","numEvents":13,"numAffected":13,"numAtRisk":202},{"groupId":"EG002","numEvents":23,"numAffected":22,"numAtRisk":202},{"groupId":"EG003","numEvents":12,"numAffected":12,"numAtRisk":198},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":113},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":109},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":104},{"groupId":"EG007","numEvents":6,"numAffected":6,"numAtRisk":116}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":201},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":202},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":202},{"groupId":"EG003","numEvents":6,"numAffected":5,"numAtRisk":198},{"groupId":"EG004","numEvents":6,"numAffected":6,"numAtRisk":113},{"groupId":"EG005","numEvents":5,"numAffected":5,"numAtRisk":109},{"groupId":"EG006","numEvents":7,"numAffected":5,"numAtRisk":104},{"groupId":"EG007","numEvents":4,"numAffected":4,"numAtRisk":116}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":true},"pointOfContact":{"title":"Moderna WeCare Team","organization":"ModernaTX, Inc.","email":"WeCareClinicalTrials@modernatx.com","phone":"+1-866-663-3762"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2021-12-09","uploadDate":"2025-07-25T12:16","filename":"Prot_001.pdf","size":1707518},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2023-04-19","uploadDate":"2025-07-25T12:16","filename":"SAP_002.pdf","size":1527094},{"typeAbbrev":"ICF","hasProtocol":false,"hasSap":false,"hasIcf":true,"label":"Informed Consent Form","date":"2021-10-07","uploadDate":"2024-09-26T17:13","filename":"ICF_000.pdf","size":444943}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2025-08-12","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D000071243","term":"Zika Virus Infection"}],"ancestors":[{"id":"D000096724","term":"Mosquito-Borne Diseases"},{"id":"D000079426","term":"Vector Borne Diseases"},{"id":"D007239","term":"Infections"},{"id":"D001102","term":"Arbovirus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D018177","term":"Flavivirus Infections"},{"id":"D018178","term":"Flaviviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"}]},"interventionBrowseModule":{"meshes":[{"id":"C000719754","term":"GLS-5700 vaccine"}]}},"hasResults":true}